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1. REVIEW OF THE LITERATURE 
1.1 Introduction 
Water is essential for life, and providing the human population with safe drinking water is one of 
the most important issues in public health. Cyanobacteria (blue-green algae) produce toxins that 
may present a hazard for drinking water safety. These toxins (microcystins, nodularins, saxitoxins, 
anatoxin-a, anatoxin-a(S), cylindrospermopsin) are structurally diverse and their effects range 
from liver damage, including liver cancer, to neurotoxicity. The occurrence of cyanobacteria and 
their toxins in water bodies used for the production of drinking water causes a technical challenge 
for water treatment and cleaning. Toxic cyanobacteria in water used for recreational purposes 
pose a hazard to humans. Blooms of cyanobacteria accumulating along shores also present a 
hazard to wild and domestic animals.  
The presence of toxins in drinking water creates a potential risk of toxin exposure for water 
consumers. Conventional water treatment procedures (such as coagulation, flocculation, 
clarification and sand filtration) are normally efficient methods of removing cyanobacterial cells, 
but are not effective in removing or destroying dissolved cyanobacterial toxins. Besides the 
chemical and physical methods used, biological degradation could be an efficient method of water 
detoxification. 
Specific strains of Lactobacillus and Bifidobacteria have been empirically used in the production of 
fermented dairy foods, in the preservation of food and drinks, and as probiotics. Lactic acid 
bacteria have a long history of safe use in food and food fermentations, and normal healthy 
intestinal microbiota also contains many strains of lactic acid bacteria. The previously-reported 
capacity of lactic acid bacteria and bifidobacteria in removal of different complex contaminants 
led to the hypothesis of using such food grade bacteria as a possible new and safe method of 
water decontamination of cyanobacterial toxins. 
 1.2 Cyanobacteria 
Cyanobacteria, also known as blue-green algae, have a long evolutionary history and are among 
the oldest organisms in the world. There is evidence of the organisms even from around 3500 
million years ago (Schopf, 1993). Cyanobacteria carry out oxygen-evolving photosynthesis. The 
earth’s oxygen-rich atmosphere and the cyanobacterial origin of plastids in plants are the two 
major evolutionary contributions made by cyanobacteria. Certain cyanobacteria are able to carry 
out nitrogen fixation.  
Cyanobacteria occur in various environments including water, such as fresh and brackish water, 
oceans, hot springs, moist terrestrial environments such as soil, glaciers and in symbioses with 
plants, lichens and primitive animals. These organisms are often the first to colonise bare areas. 
They can also tolerate extremely high and low temperatures (Castenholz, 1973). In aquatic 
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environments, cyanobacteria are important primary producers and form a part of the 
phytoplankton. They may also form biofilms and mats (benthic cyanobacteria). In eutrophic 
water, cyanobacteria frequently form mass occurrences, so-called water blooms. Mass 
occurrences of cyanobacteria can be toxic. They have caused a number of animal poisonings and 
may also pose a threat to human health. 
Cyanobacteria are small unicellular or filamentous bacteria with some characteristics of algae, 
such as the cell wall structure, pigments like chlorophyll-a and phycobiliproteins, 70S ribosomes, 
and the ability to perform oxygenic photosynthesis (Chorus, 2001), although they have no 
membrane bound nucleus or sub-cellular organelles. They can multiply only asexually by binary 
fission, forming endospores. The photosynthetic pigments are located in thylakoids and vary from 
blue-green to violet-red. Cyanobacteria have a well-developed ability to store essential nutrients 
and metabolites, such as glycogen granules, lipid globules, cyanophycin granules and 
carboxysomes, under favourable conditions. 
Cyanobacteria produce many different classes of biologically active compounds, including 
hepatotoxic cyclic peptides, microcystins and nodularins, cytotoxic cylindrospermopsins, 
neurotoxic anatoxin-a and -a(S), saxitoxins, neurotoxic amino acid β-N-methylamino-L-alanine 
(BMAA) and non-toxic irritating lipopolysaccharides (reviewed in Sivonen and Jones, 1999; 
Meriluoto and Codd, 2005; Hudnell, 2008), see sections 1.4.1–1.4.6. Although both neurotoxins 
and hepatotoxins are distributed worldwide (Carmichael, 1992 and 1994), it appears that 
hepatotoxic blooms of cyanobacteria are more commonly found than neurotoxic blooms, and 
neurotoxins are considered to be of lower risk as they are less stable (Fawell et al., 1994). In 
contrast, hepatotoxins are highly stable and exposure to these toxins has resulted in significant 
toxicity to both animals and humans. 
Cyanobacteria are ubiquitous in their distribution in both fresh and marine waters. Toxic 
cyanobacterial blooms have been reported in most parts of the world (reviewed in Chorus and 
Bartram, 1999) (Table 1.1). Cyanobacterial blooms are a result of the increasing eutrophication in 
waterbodies (Chorus and Bartram, 1999). Most of these cyanobacteria are harmful to animals and 
humans because of their production of toxins.  
1.3 Conditions of cyanobacterial bloom formation 
Over the past several centuries, human nutrient over enrichment in water, particularly nitrogen 
and phosphorus, associated with urban, agricultural and industrial development, has promoted 
eutrophication, which favours algal and cyanobacterial bloom formation. Decay of these excessive 
blooms results in decreased dissolved oxygen and the release of cyanotoxins in the water, which 
can result in mortality of animals and even humans (Chorus and Bartram, 1999). Prevention of 
bloom formation is therefore the most efficient method for avoiding cyanobacterial toxin 
contamination of drinking water. 
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Most cyanobacteria are planktonic, while some attach to sediments or surfaces and are benthic, 
others occur as single cells or filaments and colonies. Some cyanobacteria accumulate near the 
surface as blooms or scums and their growth is favoured by optimal pH, temperature, humidity, 
nitrogen, phosphorous, salinity, micronutrients, turbidity and light (Utkilen and Gjølme, 1992). 
Rain, heavy winds or cooler temperatures often inhibit growth or break up the bloom, mixing it 
into the water body. However, under continuing favourable conditions blooms may last for 
several weeks. 
Cyanobacteria require low energy to maintain cell function and structure. While high turbulence 
and high water flows are unfavourable, macrophytes compete with cyanobacteria for nutrients 
and light, suppressing their growth. High temperature offers competitive advantage to 
cyanobacteria over phytoplankton. The pigments in cyanobacteria use the green, yellow and 
orange wavelengths of the spectrum (500–650 nm), which are hardly used by phytoplankton. 
Most cyanobacteria are sensitive to high light intensities, but those that form blooms are more 
resistant (Paerl and Paul, 2011).  
Cyanobacterial water blooms can be observed as greenish scum (or red-brown in the case of red-
pigmented strains) floating in surface water. However, some cyanobacteria, such as 
Cylindrospermopsis and Planktothrix, bloom in deeper water layers and may not produce obvious 
blooms. Masses of floating scum prevent the use of water for recreation and may spoil the taste 
of water because of strongly odorous metabolites. Poisonings caused by the cyanotoxins 
produced during heavy blooms have affected both humans and wild and domestic animals. Both 
hepatotoxic and neurotoxic poisonings have been associated with mass occurrences of 
cyanobacteria (Carmichael, 1997; Chorus and Bartram, 1999). 
1.3.1 Toxin release 
Most of the cyanotoxins remain in the cell until the cell is lysed. If high extracellular toxin 
concentrations are present in the raw water, problems will occur for drinking water treatment 
plants. Under natural circumstances high toxin concentrations appear during the breakdown of a 
cyanobacterial bloom. Cyanobacterial cells are also lysed in the presence of chemicals, such as 
potassium permanganate or chlorine (Kenefick et al., 1993; Romanowska-Duda et al., 2001), 
which can inhibit bacterial cell wall synthesis and enzymatic reactions. Copper sulphate also leads 
to a lysis of cyanobacterial cells, which is followed by the release of the intracellular toxins into 
the water (Kenefick et al., 1993; Jones and Orr, 1994; Hawkins et al., 2001). The use of these kinds 
of chemicals to inhibit cyanobacterial growth and clean the water has led to several intoxications 
of livestock. A case of severe intoxication of humans was reported in Australia after treatment of 
the drinking water dam with copper sulphate (Bourke et al., 1983).  
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Table 1.1. Examples of distribution of cyanobacterial toxins in different parts of the world 
Country Year(s) of research Toxins Reference 
Algeria 2001 MCs Bouaïcha and Nasri, 2004; Nasri et al., 2004 
Argentina 1998–2000 MCs Conti et al., 2005 
Australia 1991, 1995-2001 MCs, NOD, CYN, 
saxitoxins 
Jones et al., 1994 and 1995; Negri et al., 1995; Hawkins 
et al., 1997; Kankaanpää et al., 2005  
Brazil 1995–97 MCs, saxitoxins Lagos et al., 1997; Hirooka et al., 1999 
Canada 1990 MCs  Harada et al., 1991; Kotak et al., 1993 
Chile 1998 MCs Neumann et al., 2000 
China 1988, 2003  MCs Zhang et al., 1991; Chen and Xie, 2005 
Denmark 1992–95 MCs, anatoxin-
a(S) 
Christoffersen, 1996; Henriksen and Moestrup, 1997; 
Onodera et al., 1997a 
Finland and 
Baltic sea 
1989, 1994–95, 
1985-87 
MCs, anatoxin-a, 
NOD 
Sivonen et al., 1990, Lahti et al., 1997;  
Sivonen et al., 1989 
France 1994  MCs Vezie et al., 1997 
Germany 1992, 1995-96, 
1999, 2000 
MCs, anatoxin-a Fastner et al., 1995 and 1999; Ueno et al., 1996; Bumke-
Vogt et al., 1999; Chorus, 2001 
Greece 1987 MCs Lanaras et al., 1989 
Japan 1988–92, 1992–95, 
1998–2000 
MCs, anatoxin-a, 
CYN 
Watanabe et al., 1992; Park et al., 1993a and b; Tsuji et 
al., 1996; Ueno et al., 1996; Harada et al., 2004; Ozawa 
et al., 2005 
Kenya 1998–2000 MCs Mwaura et al., 2004 
Netherlands 2000–02 MCs Janse et al., 2005 
Poland 2002 MCs Mankiewicz et al., 2005 
Portugal 1989–92 MCs Vasconcelos et al., 1996 
South Africa 1985–86 MCs Wicks and Thiel, 1990 
Spain 2000 MCs Moreno et al., 2004; Aboal and Puig, 2005 
Turkey 2000–03 MCs Albay et al., 2005 
UK 1990-92 MCs, anatoxin-a Edwards et al., 1992; Codd et al., 1995 
USA 1993, 2000–01 MCs, saxitoxins McDermott et al., 1995; Carmichael et al., 1997; 
Onodera et al., 1997b; Graham et al., 2004 
 
1.4 Cyanobacterial toxins 
The conditions leading to cyanobacterial proliferation are well established, but the physiological 
or biochemical functions of the cyanobacterial toxins are largely unknown. Cyanobacteria produce 
a variety of toxins that are classified functionally into hepato-, neuro-, and cytotoxins. 
Additionally, cyanobacteria produce lipopolysaccharides as well as secondary metabolites that 
might be useful pharmacologically. Most of the cyanotoxins originate from planktonic 
cyanobacteria, which occur in fresh and brackish water. Toxic strains of cyanobacteria have also 
been isolated from benthic environments. The following sections describe toxins produced by 
cyanobacteria more in detail. 
Detection methods for cyanobacterial toxins include biochemical methods, such as nucleic acid 
based methods, enzyme-linked immunosorbent assay (ELISA) and protein phosphatase inhibition 
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assay (PPIA), and physico‐chemical methods, such as high-performance liquid chromatography 
(HPLC) and liquid chromatography-mass spectrometry (LC-MS) (reviewed e.g. in van Apeldoorn et 
al., 2007). The development of methods for cyanotoxin analysis has not been the aim of this 
thesis and therefore the methods are not described more in detail in the thesis. 
1.4.1 Microcystins 
Globally, the most frequently reported cyanobacterial toxins are cyclic heptapeptide 
hepatotoxins, microcystins. These can be found primarily in some species of the freshwater 
genera Microcystis, Anabaena, Planktothrix, Nostoc, and Anabaenopsis. Microcystins are named 
after Microcystis aeruginosa, the cyanobacterium in which the toxin was first isolated and 
described (Carmichael et al., 1988).  
Microcystins are cyclic heptapeptides with variable amino acids and a general structure of 
cyclo(‐D‐Ala
(1)
–L-X
(2)
–D‐MeAsp(iso-linkage)
(3)
–L-Z
(4)
–Adda
(5)
–D‐Glu(iso-linkage)
(6)
–Mdha
(7)
, in which 
amino acid residues at 2 and 4 are variable L-amino acids, D-MeAsp is D-erythro-β-methylaspartic 
acid, and Mdha is N-methyldehydroalanine, while the amino acid Adda is (2S,3S,8S,9S)-3-amino-9-
methoxy-2,6,8-trimethyl-10-phenyldeca-4(E),6(E)-dienoic acid (Fig. 1.1). The Adda component of 
microcystins is contributing to their toxicity (Carmichael, 1992; Ressom et al., 1994). There are 
around 100 structural variants of microcystins described in the literature (listed in Sivonen and 
Jones, 1999; Spoof, 2004; Neffling, 2010), formed by variation in all 7 amino acids, primarily the L-
amino acids at position 2, 3, 4, or 7. The main structural differences between microcystin variants 
such as -LR, -LA, -RR, and -YR are the substitution of single amino acids.  
The most widely-distributed (Carmichael, 1992) and studied microcystin variant is microcystin-LR 
(MC-LR), with the amino acid residues leucine and arginine in positions 2 and 4, respectively. MC-
LR is produced as a secondary metabolite mostly by Microcystis species as well as other 
cyanobacteria (Bishop et al., 1959; Dittmann et al., 1997; Nishizawa et al., 1999). It is a water-
soluble and a non-volatile toxin with a molecular weight of 994. Production of MC-LR is 
dependent on various factors like strain specificity, genetic differences, metabolic processes 
required for toxin production and can differ temporally and spatially (Ressom et al., 1994). A 
single bloom can have both toxigenic and non-toxigenic strains within it, and the extent of toxicity 
depends on the dominance of toxic strains within the bloom (Chorus and Bartram, 1999). The 
toxins are generally bound to the cell membrane and are released as cells age and die, and under 
stress. They can also passively leak out of cells or be released by lytic bacteria (Carmichael, 1992). 
MC-LR is hepatotoxic and is a potent tumour promoter. The primary target organ of MC-LR is the 
liver (Falconer et al., 1983; Runnegar and Falconer, 1986; Brooks and Codd, 1987; Meriluoto et al., 
1990; Nishiwaki et al., 1994) although it also affects the kidney, gastrointestinal tract and colon 
(Bell and Codd, 1994). Microcystins are taken up into the cells through the organic anion 
transporting polypeptides (Feurstein et al., 2009), formerly called the bile acid transport system 
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(Falconer and Yeung, 1992; Ito et al., 2000), as they are unable to penetrate the cell membrane 
(Eriksson et al., 1990). The more lipophilic microcystin variants, such as MC‐LW and MC‐LF, have 
been shown to interact more efficiently with a model membrane than MC‐LR, suggesting more 
interactions with cell membranes (Vesterkvist and Meriluoto, 2003). In the liver, MC-LR induces 
cytoskeletal damage, disruption of the hepatic structure, necrosis and haemorrhage (Beasley et 
al., 2000; Hooser, 2000). MC-LR also results in liver enlargement, decreased systemic arterial 
blood pressure and eventually death (Beasley et al., 2000).  
Microcystins are potent and specific inhibitors of serine/threonine-specific protein phosphatases 
1 and 2A (MacKintosh et al., 1990). Inhibition of phosphatases by microcystins can alter the 
balance between phosphorylation and dephosphorylation, which can affect diverse biological 
processes (Cohen, 1989). Exposure to MC-LR has also been found to result in oxidative stress, 
cytoskeletal damage, cytokine induction, mitochondrial alteration, and tumour promotion 
(Falconer and Yeung, 1992; Falconer and Humpage, 1996). The oral dose required to induce 
microcystin toxicity is higher than the intravenous or intraperitoneal dose. Yoshida et al. (1997) 
found that the intraperitoneal LD50 of MC-LR in mice was 65.4 μg/kg body weight (bw) and the 
oral LD50 was 10.9 mg/kg bw. Microcystin variants differ in toxicity, in the literature reported 
values range from the very potent toxin MC-LR, LD50 of 50 µg/kg (mouse i.p.), to MC-RR, LD50 of 
600 µg/kg (Sivonen and Jones, 1999). 
Microcystins are distributed in waterbodies worldwide, and the toxicity on exposure to 
microcystins has been reported worldwide in fish, animals and humans (reviewed in Chorus, 
2001). The World Health Organization (WHO) has set a provisional drinking water guideline of 1 
μg/L for MC-LR (WHO, 1998; new edition in WHO, 2011) (discussed in section 1.6.1).  
Microcystins are synthesised non-ribosomally by a multi-enzyme complex, comprised of 
polyketide synthases and polypeptide synthetases. These enzymes (200–2000 kDa) are composed 
of modules (mcyA – mcyJ), which are coded in one gene-cluster with ten open reading frames and 
are responsible for one synthesis step each (Neilan et al., 1999; Tillet et al., 2000; Rouhiainen et 
al., 2004). 
 
Figure 1.1. General structure of the hepatotoxic cyclic peptides, microcystins.  
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1.4.2 Nodularins 
The cyclic pentapeptide nodularin (NOD) is common in brackish water. It occurs in the Baltic Sea 
as well as in saline lakes and estuaries. In the Baltic Sea, marine blooms of Nodularia spumigena 
are among some of the largest cyanobacterial mass events in the world. Nodularin has also been 
found in Australia. The first scientific report of the potent toxicity of cyanobacterial blooms was 
published in Nature by G. Francis in 1878, where the author reported that stock deaths had 
occurred as a result of drinking from a lake polluted by a bloom in Australia. The organism 
responsible for this bloom was later described as Nodularia spumigena and the toxin was later 
isolated and characterised (Rinehart et al., 1988) as nodularin. The name nodularin also originates 
from the producer cyanobacterium, Nodularia spumigena (Rinehart et al., 1998). Less than 10 
analogues of nodularins are known (Chorus and Bartram, 1999). The chemical structure of 
nodularin is cyclo(D-MeAsp(iso-linkage)
(1)
-L-Z
(2)
-Adda
(3)
-D-Glu(iso-linkage)
(4)
-Mdhb
(5)
), in which 
Mdhb is 2-(methylamino)-2-dehydrobutyric acid (Fig. 1.2). The second residue (Z) is L-Arg in the 
common nodularin-R, with a molecular weight of 824, and L-Val in nodularin-V isolated from the 
marine sponge Theonella (de Silva et al., 1992). A few naturally occurring variants of nodularins 
have been found (Namikoshi et al., 1994). 
 
Figure 1.2. General structure of nodularins. 
1.4.3 Cylindrospermopsin 
Cylindrospermopsin (CYN), originally isolated from the cyanobacterium Cylindrospermopsis 
raciborskii, is an alkaloid cytotoxin with the structure of a tricyclic guanidine moiety attached to a 
hydroxymethyluracil (Ohtani et al., 1992) and a molecular weight of 415 (Fig. 1.3). It is also known 
to be produced by other cyanobacteria, such as Aphanizomenon ovalisporum and Anabaena 
bergii. Cylindrospermopsin inhibits protein synthesis and mainly affects the liver (Terao et al., 
1994), but can also affect the kidney, spleen, thymus, and heart. It is a cyanotoxin occurring in 
tropical or subtropical regions that has recently been detected also in temperate regions. 
Cylindrospermopsin-producing cyanobacteria have been reported e.g. in Australia (Ohtani et al., 
1992; Shaw et al., 1999), Japan (Harada et al., 1994), Israel (Banker et al., 1997), New Zealand 
(Stirling and Quilliam, 2001) and Finland (Spoof et al., 2006). A similar guideline value as for MC-
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LR, a 1 µg/L guideline value for cylindrospermopsin in drinking water has been proposed by 
Humpage and Falconer (2003). 
New structural variants of cylindrospermopsin have been isolated (Li et al., 2001; Mazmouz et al., 
2010). One variant was identified as deoxycylindrospermopsin by Norris et al. (1999), and was 
reported to be nearly non-toxic. Banker et al. (2000) elucidated the chemical structure of 7-
epicylindrospermopsin and it was shown to be toxic. The uracil moiety is important for the toxicity 
of cylindrospermopsin.  
 
Figure 1.3. Structure of cylindrospermopsin. 
1.4.4 Neurotoxins 
Cyanobacterial neurotoxins belong to a diverse group of heterocyclic compounds called alkaloids. 
Three types of cyanobacterial neurotoxins, anatoxin-a, anatoxin-a(S), and saxitoxins, are known. A 
mild neurotoxin, BMAA, has been found in a variety of cyanobacteria (Cox et al., 2005; Metcalf et 
al., 2008).  
Anatoxin-a is a small alkaloid with a molecular weight of 165, a secondary amine with the 
structure 2-acetyl-9-azabicyclo(4-2-1)non-2-ene (Devlin et al., 1977). It mimics the effect of 
acetylcholine and causes rapid death by respiratory arrest. Homoanatoxin-a (MW 179) is an 
anatoxin-a homologue. It has a propionyl group at C-2 instead of the acetyl group found in 
anatoxin-a and has been found in Oscillatoria formosa (Skulberg et al., 1992).  
Anatoxin-a has been shown to be produced by several Anabaena, Aphanizomenon, Oscillatoria 
and Planktothrix species (reviewed in Sivonen and Jones, 1999). Anatoxin-a is perhaps the most 
common cyanobacterial neurotoxin, especially in North America and Europe, and has caused 
numerous animal poisonings. 
Anatoxin-a(S) is a phosphate ester of a cyclic N-hydroxyguanine, originally identified from 
Anabaena flos-aquae strain NRC 525-17 (Matsunaga et al., 1989). The molecular weight is 252. 
Anatoxin-a(S) is an irreversible acetylcholine esterase inhibitor and its characteristic signs of 
poisonings in mice include salivation. Anatoxin-a(S) was first reported in North America where it 
has caused animal poisonings and later also in Denmark (Onodera et al., 1997a). 
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Saxitoxins, also known as paralytic shellfish poisons (PSP toxins) were originally isolated and 
characterised from marine dinoflagellates (Anderson, 1994). Saxitoxins are sodium channel 
blocking agents causing paralysis and have caused human poisonings due to their ability to 
concentrate in shellfish (Anderson, 1994). In cyanobacteria, saxitoxins have been found in 
Anabaena circinalis, Anabaena lemmermannii, Aphanizomenon flos-aquae, Cylindrospermopsis 
raciborskii and Lyngbya wollei (Humpage et al., 1994; Onodera et al., 1997b; Pereira et al., 2000). 
1.4.5 Lipopolysaccharides 
Lipopolysaccharide (LPS) endotoxins are generally found in the outer membrane of the cell wall of 
Gram-negative bacteria, also in cyanobacteria. Bacterial LPS are pyrogenic and toxic (Weckesser 
and Drews, 1979). It is often the fatty acid component of LPS that elicits an irritant, pyrogenic or 
allergenic response in humans and mammals. Cyanobacterial LPS may contribute to human health 
problems via exposure to mass occurrences of cyanobacteria. 
1.4.6 Other bioactive compounds from cyanobacteria 
Cyanobacteria have been found to be a rich source of new bioactive compounds for the 
biotechnological and biomedical industries (Burja et al., 2001; Singh et al., 2005). Cyanobacteria 
produce bioactive compounds that are effective both against eukaryotic cells and also against 
viruses, bacteria and other cyanobacteria. Many of the bioactive cyanobacterial compounds are 
peptides (Fujii et al., 2002). Bioactive compounds may have various biological activities in test 
animals, eukaryotic or prokaryotic cells or viruses, or they may target certain enzymes. Marine 
environments and especially benthic cyanobacteria seem to be among the best sources of new 
bioactive compounds. Much interest has been focused on screening anticancer compounds.  
1.5 Occurrence and levels of cyanobacteria and hepatotoxins 
Toxic cyanobacteria are found worldwide both in inland and coastal water environments. They are 
widespread and found in a diverse range of environments, including soils, seawater and 
freshwater environments. Some environmental conditions, including sunlight, warm weather, low 
turbulence and high nutrient levels, can promote growth. Depending on the species, this may 
result in green discolouration of water due to a high density of suspended cells and the formation 
of surface scums. Such cell accumulations may lead to high toxin concentrations.  
The toxins are not actively secreted to the surrounding water; most of the toxin is intracellular in 
growing cells. The release of toxin occurs during senescence of the cultures and when cultures 
shift from growth phase to stationary and death phases. Studies with laboratory cultures have 
shown that more than 80% of the microcystin or nodularin is intracellular in growing cells (Codd et 
al., 1989; Sivonen, 1990; Rapala et al., 1997). Also under field conditions, the majority of 
microcystin is intracellular during active growth of the cells (Jones and Orr, 1994; Lahti et al., 
1997). Cylindrospermopsin on the other hand is also produced extracellularly and high 
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concentrations of dissolved toxin can be found in cyanobacterial cultures producing 
cylindrospermopsin (Metcalf et al., 2002). 
Globally it appears that hepatotoxic freshwater blooms of cyanobacteria are more commonly 
found than neurotoxic blooms. There are reports of hepatotoxic blooms from all continents 
around the world (examples found in Table 1.1). Mass occurrences of neurotoxic cyanobacteria 
are common in some countries and have been reported in North America, Australia and Europe, 
where they have caused several animal poisonings (e.g. Repavich et al., 1990; Baker and 
Humpage, 1994; Bumke-Vogt et al., 1999). 
Some of the highest reported cyanotoxin concentrations in bloom samples, measured by HPLC, 
have been 7300 µg/g dry weight (dw) microcystin in a Microcystis bloom from China (Zhang et al., 
1991), 18000 µg/g dw nodularin in a Nodularia bloom from the Baltic sea (Kononen et al., 1993) 
and 5500 µg/g dw cylindrospermopsin from Australia (Sivonen and Jones, 1999). For water 
treatment and public health management purposes, a more appropriate unit is often toxin 
concentration per litre of water, for example in relating toxin concentrations to the WHO 
guideline level of 1µg/L of MC-LR (described in section 1.6.1). High concentrations of microcystins 
per litre of water have been reported among others in Germany, up to 25000 μg/L microcystin 
(Chorus, 1998). The quantitative determination of toxins is mostly performed from lyophilised 
cultures, bloom samples or seston. Results are usually expressed as milligrams or micrograms of 
toxin per gram of dw. 
Toxic and non-toxic strains from the same cyanobacterial species cannot be separated by 
microscopic identification. To confirm that a particular cyanobacterial strain produces toxins, it is 
important to isolate a culture of that strain, and to detect and quantify toxin concentrations in the 
pure culture. The use of molecular genetic methods has further lead to the development of more 
precise identification methods for toxic cyanobacteria.  
1.6 Human health effects 
Many cyanobacteria produce potent toxins. As reported in literature, problems caused by 
cyanobacteria are encountered around the world and problems related to safe drinking water 
production are common (reviewed in e.g. Codd et al., 2005). The human health effects caused by 
cyanobacterial toxins vary in severity from mild gastroenteritis to severe and sometimes fatal 
diarrhoea, dysentery and hepatitis. Each toxin has specific properties, with individual concerns 
including liver damage, neurotoxicity and tumour promotion. Microcystins, including the most 
common variant MC-LR, are hepatotoxic and potent tumour promoters. Acute symptoms 
reported after exposure to microcystin-containing cyanobacteria include gastrointestinal 
disorders, nausea, vomiting, fever and irritation of the skin, ears, eyes, throat and respiratory 
tract, abdominal pain, kidney and liver damage. There are several reports of human health effects 
associated with ingestion of water containing microcystins, with effects ranging from 
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gastroenteritis (Annadotter et al., 2001) to liver damage (Falconer et al., 1983) and even death 
(Teixera et al., 1993) (discussed in section 1.6.2).  
Humans can be exposed to a range of cyanotoxins contained either in cyanobacterial cells or 
released into the water. The dissolved toxins are stable against low pH and enzymatic degradation 
and will therefore remain intact within the digestive tract. As microcystins do not readily 
penetrate the cell membrane (Eriksson et al., 1990), they enter the body from the intestine via 
the organic anion transporting polypeptides (Feurstein et al., 2009). As a consequence of active 
transport, the toxicity of microcystins is restricted to organs expressing a suitable transporter, 
such as the organic anion transporter in the cell membranes. From the blood microcystins are 
then concentrated in the liver as a result of active uptake by hepatocytes (Runnegar et al., 1981). 
The toxins are covalently bound to protein phosphatases in the hepatocyte cytosol (Bagu et al., 
1997). Some more hydrophobic microcystin variants may cross cell membranes by other 
mechanisms, including diffusion (Vesterkvist and Meriluoto, 2003). 
Microcystins act primarily through inhibition of protein serine/threonine phosphatases 1 and 2A 
(Honkanen et al., 1990; MacKintosh et al., 1990; Runnegar et al., 1993). These enzymes are 
essential in cellular regulation and inhibition results in a higher level of protein phosphorylation in 
hepatocytes, which will lead to cytoskeletal damage and haemorrhage in the liver. Furthermore, 
the excessive signalling may lead to cell proliferation, cell transformation and tumour promotion 
(Fujiki and Suganuma, 1993). In hepatocytes protein phosphatase inhibition also causes disruption 
of intermediate actin filaments and microtubules leading to cellular disruption (Falconer and 
Yeung, 1992; Wickstrom et al., 1995; Khan et al., 1996). 
Human health problems are often associated with chronic exposure to low microcystin 
concentrations in poorly treated drinking water, contaminated food (such as fish, mussels and 
prawns) or with the consumption of algal supplements contaminated with cyanotoxins (Gilroy et 
al., 2000; Lawrence et al., 2001). Exposure routes include the oral route, through inhalation or 
through dermal exposure. Human exposure to MC-LR primarily occurs through ingestion of 
contaminated drinking water (Gupta, 1998). Accidental ingestion of contaminated water during 
recreation is also possible. Another route of uptake is the nasal mucosa (Chorus et al., 2000). 
During recreational activities in cyanobacterial contaminated water bodies toxins might flow into 
the respiratory tract (Chorus et al., 2000). Renal dialysis patients are at great risk when water used 
for dialysis contains contaminants such as cyanotoxins. For these patients large volumes of water 
are used and the route of exposure is similar to the i.v. route, which leads to a greater uptake of 
toxin than through oral ingestion (see section 1.6.1). 
The use of water containing cyanobacterial toxins for irrigation of crops presents potential health 
hazards through several exposure routes, including uptake into the food chain. There are several 
reports on plants taking up microcystins from the irrigation water (Abe et al., 1996; Kos et al., 
1995; Järvenpää et al., 2007). 
 
Review of the Literature 
 
23 
In some countries cyanobacteria are sold as dietary supplements, containing the cyanobacteria 
Arthrospira (Spirulina) and Aphanizomenon flos-aquae. Therefore a possible route for toxin 
exposure is due to consumption of cyanobacterial health food tablets (Gilroy et al., 2000; 
Lawrence et al., 2001). The dermal route may play a role during recreational use of water 
(swimming, canoeing etc.) (Falconer, 1996 and 1999), but due to the hydrophilic character of 
most microcystins, anatoxins, cylindrospermopsins and saxitoxins, an uptake via the skin is 
unlikely. Dermal contacts cause skin irritations, such as allergic reactions, but have not been 
widely reported. 
1.6.1 Reported cases of cyanotoxin exposure 
Exposure to cyanotoxins has been reported worldwide in humans and animals for over a century 
(Francis, 1878). Some incidents are listed in Table 1.2. Exposure most often occurs orally, but can 
also occur through inhalation or through skin exposure. Human exposure to MC-LR is primarily 
through ingestion of contaminated drinking water (Gupta et al., 1998) and by recreational contact 
with contaminated water, by consumption of fish or cyanobacterial products from contaminated 
water. Even minor contact with cyanobacteria in bathing water can lead to skin irritation and 
increased probability of gastrointestinal symptoms (Pilotto et al., 1997). 
The two most lethal poisonings by cyanobacteria in drinking water have occurred in Brazil. A 
severe gastro-enteritis epidemic affecting about 2000 persons, of which 88 died, followed the 
flooding of a newly built dam reservoir (Itaparica Dam) in Brazil in 1988 (Teixeira et al. 1993). Both 
water samples from the dam and blood and faecal samples from the patients were subjected to 
bacteriological, virological and toxicological tests. The results showed that toxins produced by 
cyanobacteria present in a bloom of Anabaena and Microcystis in the dam water were responsible 
for the epidemic (Teixeira et al. 1993). In 1996, an outbreak of severe hepatitis occurred at a 
Brazilian haemodialysis centre in Caruaru, Brazil. At this clinic 117 of 136 patients experienced 
visual disturbances, nausea, vomiting, muscle weakness and painful hepatomegaly, following 
routine haemodialysis treatment. Later, 100 patients developed acute liver failure and 76 of the 
patients died. MC-LR and other microcystin congeners were found in the water and also blood 
and liver tissue samples from the patients were verified to contain microcystins (Pouria et al., 
1998; Jochimsen et al., 1998; Carmichael et al., 2001; Yuan et al., 2006; Hilborn et al., 2007). 
Cylindrospermopsin was also found in the clinic’s filtration system (Carmichael et al., 2001). 
There have been many incidences of human illness through drinking water in Australia and North 
America, where microcystins have been present in the water (Bourke et al., 1983; Falconer, 1989 
and 1996). The earliest incidence of cyanotoxin exposure in North America was reported in 1931, 
where 5000–8000 people who consumed water from Ohio and Potomac rivers containing a 
Microcystis-bloom showed symptoms of gastroenteritis and illness (Tisdale, 1931). In 1975, 
endotoxic shock of 23 dialysis patients in Washington DC was attributed to cyanobacterial 
contamination in a drinking water reservoir (Hindman et al., 1975). 
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The high prevalence of primary liver cancer in regions of China, where pond and ditch water are 
used as drinking water supplies, has been investigated and discussed by several authors, and 
chronic effects of long-term exposure to microcystins in drinking water have been considered (Yu, 
1989; Harada et al., 1996; Ueno et al., 1996). Cyanobacteria are abundant in surface waters in 
South East China where the incidence of hepatocellular carcinoma is highest, and it has been 
proposed that microcystins in the drinking water are responsible for the higher incidences of 
cancer in persons drinking the pond and ditch water (Yu, 1995; Yu et al., 2001). In China MC-LR 
exposure through drinking water has also been related to colorectal cancer in the population 
(Zhou et al., 2000 and 2002).  
In 1995, adverse health effects after recreational water contact in Australia were observed in 852 
persons. Results showed an elevated incidence of diarrhoea, vomiting, flu-like symptoms, skin 
rashes, mouth ulcers, fevers, and eye or ear irritations within a week following exposure (Pilotto 
et al., 1997). Symptoms correlated significantly with duration of water contact and cell density of 
cyanobacteria. 
Numerous cases of animal poisoning (often lethal) after exposure to cyanobacteria have also been 
reported in literature. One severe mammalian poisoning incident was the deaths of sheep 
drinking from a farm dam contaminated with the neurotoxin saxitoxin in Australia (Negri et al., 
1995). There are also several other incidents that have resulted in animal poisoning and death, 
such as fish and bird deaths in Finland, dog deaths in the UK and 2000 deaths of livestock in 
Australia (Eriksson et al., 1986; Pearson et al., 1990; Humpage et al., 1994). Codd et al. (2003) 
summarised studies of cyanotoxin-related mortalities of flamingos. In the flamingos toxins were 
found in intestinal tissue, but also in the feathers of the birds (Krienitz et al., 2003; Metcalf et al., 
2006).  
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Table 1.2. Examples of incidents with cyanotoxin contamination 
Location Year Incident 
Cyanobacteria 
or toxin 
Reference 
Lake Alexandrina, Australia 1878 Deaths of sheep, horses, 
dogs, pigs 
NOD Francis, 1878 
Ohio River, USA 1931 Humans, gastro-enteritis Microcystis sp. Tisdale, 1931 
Zimbabwe 1966 Humans,  
gastro-enteritis 
M. aeruginosa Zilberg, 1966 
Palm Island, Australia 1979 Humans, hepato-enteritis CYN Bourke et al., 1983 
Armidale, Australia 1981 Humans, liver damage M. aeruginosa Falconer et al., 1983 
Porvoo, Finland 1984 Dog deaths NOD Persson et al., 1984 
Åland Islands, Finland 1985 Fish and bird deaths MC Eriksson et al., 1986 
Richmond Lake, USA 1988 Poisoning of livestock, 
dogs, fish, birds 
Anatoxin-a(S) Mahmood et al., 1988 
England, UK 1988 Dog deaths MC Pearson et al., 1990 
Itaparica Dam, Brazil 1988 Humans, 88 deaths, 
gastro-enteritis 
Anabaena sp.  
Microcystis sp. 
Teixeira et al., 1993 
Darling River, Australia 1990–91 Livestock, 2000 deaths Saxitoxins Humpage et al., 1994 
Loch Insh, Scotland, UK 1990–91 Dog poisonings Anatoxin-a Edwards et al., 1992 
Nandong District, Jiangsu 
Province, Shanghai, China 
1993–95 Liver cancer in population 
drinking surface water 
MC Yu, 1995; Ueno et al., 
1996 
Loch Leven, Scotland, UK 1994 Fish deaths MC Rodger et al., 1994 
Scania, Sweden 1994 Humans, gastro-enteritis MC Annadotter et al., 2001 
Australia 1994 Sheep deaths Saxitoxins Negri et al., 1995 
New South Wales, 
Australia 
1995 Health effects in 852 
humans 
Toxin not 
identified 
Pilotto et al., 1997 
Caruaru, Brazil 1996 Hemodialysis patients, 
76 deaths 
MC Jochimsen et al., 1998; 
Pouria et al., 1998; 
Carmichael et al., 2001 
North Island, New 
Zealand 
2005 Dog deaths Anatoxin-a Wood et al., 2007 
 
1.6.2 Risk assessment 
Many reported incidents of human health effects have involved inappropriate treatment of water 
supplies. The health risk caused by cyanotoxin exposure is difficult to quantify, since the actual 
exposure and resulting effects have not been conclusively determined. The most likely route for 
human exposure is the oral route via drinking water (Falconer, 1996 and 1999), and from 
recreational use of lakes and rivers (Pilotto et al., 1997).  The growth of cyanobacteria in lakes and 
rivers used for recreational purposes is today recognised as a public health issue. Water blooms of 
cyanobacteria may be associated with unpleasant odours and appearance of shores. As adequate 
surveillance for toxin production is often difficult, the users need to be alert for safe use of 
recreational water. 
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Due to the growing concern about health effects of cyanotoxins especially via drinking water, 
WHO has adopted a provisional guideline value of 1.0 μg/L for MC-LR in 1998 (WHO, 1998). The 
newest 4
th
 edition to the drinking water guideline was published in 2011 (WHO, 2011). This 
guideline value is based on a tolerable daily intake (TDI) value derived from two animal studies 
(Falconer et al., 1994, Fawell et al., 1994); a mouse study and a pig study. The first study was a 13-
week mouse oral study with pure MC-LR, which determined a provisional TDI of 0.04 μg/kg body 
weight per day for MC-LR. It was supported by a 44-day pig oral study with exposure to an extract 
from M. aeruginosa containing MC-LR in the drinking water of the animals, which resulted in a 
provisional TDI of 0.067 μg/kg body weight per day. The WHO guideline value was derived based 
on a no‐observed‐adverse‐effect level for mice and pigs using the lower of these two values and 
the TDI was calculated using an uncertainty factor of 1000. This provisional guideline value is 
applicable only for MC-LR, since the database for other microcystin variants is too small to derive 
a TDI. The directive concerning the management of bathing water quality (Directive 2006/7/EC) 
also acknowledges the managing, monitoring and classification of bathing water quality and the 
provision of information to the public on bathing water quality. 
Assessment of different water treatment procedures has shown that many of the treatment 
methods result in a reduction of cyanotoxin concentrations to below acutely toxic levels and 
below the WHO guideline value of 1.0 μg/L MC-LR in drinking water. During a cyanobacterial 
bloom the treatment procedures may however be insufficient, and also when water treatment 
procedures are not used in combination (such as chlorination and activated carbon). Therefore it 
is important to observe the water treatment efficiency during cyanobacterial blooms. Toxin levels 
during different steps of water treatment also have to be monitored.  
Binding to and inhibition of protein phosphatases is a key mechanism by which microcystins and 
nodularins exhibit their toxicity. It is therefore important to know if structural modifications of the 
toxin molecule change the affinity to and inhibition of the phosphatase. So far, it has been shown 
that neither the Adda residue alone (Namikoshi et al., 1989; Choi et al. 1993) nor linear 
microcystin- or nodularin-precursor peptides bind protein phosphatases (Taylor et al., 1996).  
1.7 Drinking water and water treatment 
Water is an essential natural resource, necessary for drinking, agriculture and industrial activities. 
Contamination of water can therefore influence humans, agricultural livestock and irrigated field 
crops, as well as wildlife drinking the water or living in the aquatic environment. Drinking water 
should be pure enough to be consumed or used with low risk of immediate or long term harm. In 
most developed countries, the water supplied to households and industry is of drinking water 
standard, even though only a small proportion is actually used as drinking water or in preparation 
of food. In large parts of the world, the population has inadequate access to safe potable water 
and use sources contaminated with disease vectors, pathogens or unacceptable levels of toxins 
and other harmful substances. As the world’s population grows the pressure on both water 
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supplies and water quality increases. In many parts of the world water is a limited resource, 
although the water on the planet and the annual rainfall should be enough to exceed the needs. 
When evaluating methods for water treatment for the removal of cyanobacterial toxins, factors 
relating to intracellular and dissolved toxins should be taken into account. Cyanotoxins are 
produced within the cyanobacterial cells and thus toxin removal involves procedures to destroy or 
avoid the cells. Usually microcystin release occurs late in the exponential growth phase and 
increases during the stationary phase (Codd et al., 1989; Sivonen, 1990; Rapala et al., 1997). The 
cyanotoxins are also water soluble and therefore chemical or biological procedures reducing the 
toxicity or completely removing the toxins from the drinking water are needed. 
In cyanotoxin removal from drinking water there is a need for knowledge of the physical and 
chemical properties of the toxin, such as the hydrophobicity, molecular size, and functional 
groups, the nature of the toxin, i.e., intracellular or extracellular, cyanobacterial growth and 
bloom patterns, and effective treatment processes (Chorus and Bartram, 1999). However, these 
treatments may not be sufficient during cyanobacterial blooms or when a high organic load is 
present, and toxin levels should therefore be monitored during all steps of water treatment 
processes. Some of the important methods of drinking water treatment are shortly described in 
the following section. A more detailed review on drinking water treatment and cyanotoxin 
removal was recently published by Westrick et al. (2010). 
1.7.1 Water treatment processes 
Conventional surface drinking water treatment utilises coagulation, flocculation, sedimentation, 
filtration and disinfection as basic methods. However, conventional treatment may need to be 
optimised for cyanotoxin removal, relating to the form of the toxin to be removed (intra- or 
extracellular), the background water matrix, and possible dissolved toxin release during the 
treatment process (Falconer, 2005). 
Coagulation or flocculation involves the aggregation of smaller particles into larger particles using 
chemicals, such as ferric chloride or aluminium sulphate. Coagulation can be an efficient method 
for eliminating cyanobacterial cells from water, but soluble cyanotoxins are not very efficiently 
removed by this method (Rositano and Nicholson, 1994). Coagulation may also cause additional 
problems such as lysis of cyanobacterial cells leading to release of toxins. 
The activated carbon approach uses either powdered activated carbon, which can be added 
occasionally when there is a need, or granular activated carbon adsorbers, which are used 
continuously (Newcombe, 2002). To achieve high removal efficiencies, high doses of powdered 
activated carbon are required and the contact time is important. Both microcystins and 
cylindrospermopsin can be absorbed by activated carbon (Newcombe, 2002), but microcystin 
variants may have different adsorption efficiencies. The disposal of the carbon containing 
cyanobacterial toxins may present a challenge for this type of treatment. 
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Rapid filtration is a method usually used after a coagulation step in conventional water treatment. 
Lepistö et al. (1994) showed that rapid filtration does not effectively remove cyanobacterial cells 
from water. Conventional water treatment requires regular backwashing of the filters, but if the 
washing process is inadequately performed, lysis of cyanobacterial cells on the filters can lead to 
release of toxins into the water (Chorus and Bartram, 1999). For cyanobacteria-containing water, 
coagulation, flocculation and dissolved air flotation have been shown to be more effective than 
sedimentation (Falconer, 2005). A comparison of coagulation/flocculation/sedimentation with 
coagulation/flocculation/dissolved air flotation in the removal of Microcystis showed that the 
latter was a more efficient treatment process (Teixeira and Rosa, 2006). 
Two types of membrane filtration, microfiltration and ultrafiltration, are commonly used to 
remove contaminants from drinking water. Both microfiltration and ultrafiltration as treatments 
or in replacing the conventional sand filtration have been shown to be effective in removal of 
intact cyanobacterial cells (Zhou and Smith, 2002; Gijsbertsen-Abrahamse et al., 2006). An 
important point when considering filtration is the lysis of cells. Dissolved microcystins have been 
shown to be removed by some reverse osmosis and nanofiltration membranes, but the removal 
depends on the membrane pore size and water quality (Gijsbertsen-Abrahamse et al., 2006). 
The most common chemical oxidants used in drinking water treatment are ozone, hydroxyl 
radicals, chlorine, chlorine dioxide, chloramine and permanganate. Chlorination and ozonation are 
effective for the removal of microcystins (Nicholson et al., 1994; Newcombe, 2002). Chlorination 
can be performed by using liquified chlorine gas, sodium hypochlorite solution or calcium 
hypochlorite granules and chlorine generators. Once cyanobacterial cells have been removed 
from water, the dissolved toxins are potentially susceptible to oxidation by disinfectants. The 
efficiency of chlorination seems to depend mainly on the chloride compounds and the 
concentration used. 
Ozone can be used as a primary disinfectant. Ozone gas is formed by passing dry air or oxygen 
through a high-voltage electric field. Ozonation has been shown to be a very effective method for 
destroying microcystins and nodularins. In Europe and North America, ozonation has primarily 
been used for disinfection purposes or to remove colour and odour from water (Langlais et al., 
1991). Ozone was initially used at the beginning of water treatment mainly to inactivate viruses 
and bacteria. In recent years, many water treatment plants have included a two-stage ozonation 
treatment (Westrick, 2008; Miao et al., 2010). Ozonation has previously been shown to rapidly 
achieve destruction of microcystins, nodularin and anatoxin-a (Keijola et al., 1988; Himberg et al., 
1989). In the microcystin structure, ozone reacts with the conjugated double bond and single 
double bond in the Adda and the Mdha group, respectively (Onstad et al., 2007). 
Microcystins have been shown to be very stable under natural sunlight (Tsuji et al., 1994), 
whereas ultraviolet light around the absorption maximum of microcystins is able to decompose 
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the toxins (Tsuji et al., 1995). Ultraviolet light combined with hydrogen peroxide treatment has 
shown to be quite efficient in microcystin removal (Rositano and Nicholson, 1994). 
Furthermore, biological treatment of water is a method used for cyanotoxin removal from 
drinking water. Biologically active filtration in the form of river bank filtration and both slow and 
rapid filtration have been reported to remove or to inactivate microcystins in drinking water (e.g. 
Lahti et al., 2001; Bourne et al., 2006) and are discussed more in detail in the following section. 
1.8 Biological degradation of cyanobacterial toxins 
People are frequently exposed to cyanobacterial toxins as well as other microbial contaminants 
through drinking water. Therefore there is a need for simple, low-cost and effective water 
treatment procedures. Conventional water treatment procedures discussed in the previous 
section are in some cases insufficient in the removal of cyanobacterial toxins from drinking water, 
especially during cyanobacterial blooms. If the cyanobacterial cells are not removed by traditional 
water treatment methods, the cells and therefore the toxins remain in the drinking water and 
must be degraded to non-toxic compounds. Since microcystins have been released into the water 
body, the toxins can persist for weeks (Jones and Orr, 1994) before they are adequately degraded 
by for example bacteria.  
Different biological methods have been applied to remove cyanobacteria and their toxins 
(reviewed in Chorus and Bartram, 1999). One type of these methods is the use of microorganisms 
or biofilms capable of degrading microcystins. Biological treatment for removal of toxin 
contaminants is becoming more useful as toxins can be removed without the addition of 
chemicals that may have the potential to produce undesirable by-products. Methods utilizing 
microcystin-degrading microorganisms can be classified into two groups. One is the use of 
biofilms grown on the surface of substrates within bioreactors, such as biological sand (Bourne et 
al., 2006; Ho et al., 2006 and 2007), biofilm-reactors based on immobilised microorganisms (Tsuji 
et al., 2006), biological treatment facilities combined with conventional treatment processes 
(Saitou et al., 2002), and granular activated carbon filters (Wang et al., 2007). The other group 
depends on specific microorganisms efficient in microcystin-degradation, such as bacteria of the 
Sphingomonas sp. (Saito et al., 2003; Valeria et al., 2006) and Sphingopyxis sp. (Okano et al., 
2009). 
Different variants of microcystins have been demonstrated to be degraded after incubation with 
water from a lake in Japan, which is frequently contaminated with cyanobacteria (Ishii and Abe, 
2000). A more effective degradation was observed after adding bed sediment or mud from the 
lake, whereas no degradation could be observed after incubation with boiled water. 
Christoffersen et al. (2002) found out that bacteria can efficiently degrade microcystins in natural 
waters with previous cyanobacterial contamination and that the degradation process is rapid and 
without lag phase.  
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Many other studies have also reported biological degradation of microcystin in natural waters 
from lakes and reservoirs (Jones and Orr, 1994; Rapala et al., 1994; Cousins et al., 1996; Tsuji et 
al., 1996). Several strains of the genus Sphingomonas have been reported to degrade microcystins 
(Jones et al., 1994; Park et al., 2001; Saitou et al., 2003; Ishii et al., 2004; Harada et al., 2004; 
Valeria et al., 2006). Seventeen strains of Gram-negative bacteria with the ability to degrade 
microcystins were isolated by Lahti et al. (1997). Table 1.3 lists strains reported to degrade 
microcystins in water, and so far these appear to mostly be limited to the Sphingomonas sp. Other 
reported microcystin-degrading bacteria include Pseudomonas aeruginosa (Takenaka and 
Watanabe, 1997), Paucibacter toxinivorans (Rapala et al., 2005) and Sphingosinicella 
microcystinivorans (Maruyama et al., 2006). Recently, Gram-positive bacteria isolated from 
freshwater and identified as Arthrobacter sp., Brevibacterium sp. and Rhodococcus sp. were 
shown to remove MC-LR (Manage et al., 2009). The mechanism of MC-LR removal for 
Rhodococcus sp. C1 (Lawton et al., 2011) was shown to be similar to the previously reported 
degradation pathway for Sphingomonas by Bourne et al. (1996). 
Within the genome of the first isolated microcystin-degrading bacterium, Sphingomonas sp. ACM-
3962, Bourne et al. (1996 and 2001) identified a gene cluster, mlrA, mlrB, mlrC and mlrD, 
responsible for the degradation of MC-LR. The authors determined that the mlrA gene encoded 
an enzyme responsible for the hydrolytic cleaving of the cyclic structure of MC-LR (ring-opening at 
the Adda-Arg peptide bond). The resulting linear MC-LR molecule was then sequentially 
hydrolysed by peptidases encoded by the mlrB and mlrC genes to a tetrapeptide and further to 
smaller peptides and amino acids (Fig. 1.4). The final gene, mlrD, encoded for a possible 
transporter protein that may have allowed for active transport of microcystin or its degradation 
products. Various studies have designed qualitative polymerase chain reaction assays for 
detection of mlrA (Saito et al., 2003; Ho et al., 2006 and 2007). Saito et al. (2003) reported gene 
homologues of mlrA in two microcystin-degrading bacteria, Sphingomonas sp. MD-1 and 
Sphingomonas sp. Y2, both of which were previously isolated from Japanese lakes. More recently, 
Hoefel et al. (2009) designed and optimised a quantitative real-time polymerase chain reaction 
assay for the detection of the MlrA gene. 
 
 
 
Figure 1.4. MC-LR degradation pathway by Sphingomonas sp. ACM-3962; MlrA-C: microcystinases 
A-C (modified from Bourne et al., 1996). 
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 Table 1.3. Reported microcystin-degrading bacteria 
Bacterial strain Degradable toxins Reference 
Sphingomonas sp. MJ-PV MC-LR Jones et al., 1994 
Pseudomonas aeruginosa MC-LR Takenaka and Watanabe, 1997 
17 different strains (Gram-
negative, Proteobacteria) 
MCs Lahti et al., 1998 
Sphingomonas sp. ACM-3962 MC-LR, MC-RR Jones and Orr 1994; Bourne et al., 1996 and 
2001 
Sphingomonas sp. Y2 MC-LR, MC-RR, MC-YR, 6(Z)-
Adda-MC-LR 
Park et al., 2001; Maruyama et al., 2003 and 
2006 
Sphingomonas sp. MD-1 MC-LR, MC-RR, MC-YR Saito et al., 2003 
Sphingomona stygia MC-LR, MC-RR, MC-YR Saitou et al., 2003 
Sphingomonas sp. B9 MC-LR, MC-RR, 3-dmMC-LR, 
dhMC-LR, MC-LR-Cys, NOD 
Harada et al., 2004, Imanishi et al., 2005 
Sphingomonas sp. 7CY MC-LR, MC-RR, MC-LY, MC-LW, 
MC-LF 
Ishii et al., 2004 
Paucibacter toxinivorans sp. nov. MC-LR, MC-YR, NOD Rapala et al., 2005 
Sphingomonas sp. MDB2 MCs Maruyama et al., 2006 
Sphingomonas sp. MDB3 MCs Maruyama et al., 2006 
Sphingomonas sp. CBA4 MC-RR Valeria et al., 2006 
Sphingomonas witflariensis  LH21 MC-LR, MC-LA Ho et al., 2007 
Burkholderia sp. MC-LR, [D-Leu1]MC-LR Lemes et al., 2008 
Sphingopyxis sp. C-1 MC-LR Okano et al., 2009 
Brevibacterium sp. MC-LR Manage et al., 2009 
Arthrobacter sp. MC-LR Manage et al., 2009 
Rhodococcus sp. MC-LR Manage et al., 2009 
Methylobacillus sp. strain J10 MC-LR, MC-RR Hu et al., 2009 
Stenotrophomonas sp. strain EMS 
Microbacterium sp. 
Rhizobium gallicum 
MC-LR, MC-RR 
MC-LR 
MC-LR 
Chen et al., 2010 
Ramani et al., 2011 
Ramani et al., 2011 
 
1.9 The gut and human intestinal microbiota 
The human gastrointestinal microbiota is a complex community. Within the gastrointestinal tract, 
different habitats such as mouth, stomach, small intestine (especially lower jejunum and ileum), 
large intestine (caecum, colon) and rectum all harbour bacteria. The fully developed healthy 
human microbiota is a multifaceted ecosystem, with more than 1000 different bacterial species 
present. The microorganisms constituting the microbiota are unevenly distributed along the 
digestive tract; the stomach and duodenum having less than 10
3
 bacterial cells per gram of 
intestinal contents, ileus and distal ileum 10
2
–10
3
 cells/g and the large intestine 10
10
–10
12
 cells/g 
being the location of most microbiota activities, while the predominant genera changes from 
Gram-positive aerobes to Gram-negative anaerobes (reviewed in e.g. Patel and Lin, 2010). The 
species appearing in the different parts are selected on the basis of the environmental conditions 
present, such as acidity and the availability of nutrients and oxygen. 
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Bifidobacteria form a minor part in the human adult microbiota, even though they form the 
predominant genus of the neonate microbiota (Conway, 1995). It is therefore believed that by 
adding these bacteria as probiotics to the diet, the normal microbiota can be altered. This 
alteration might then prevent the adhesion of pathogenic organisms, modulate bacterial enzyme 
activity and influence the gut mucosal permeability (Salminen et al., 1996).  
The main site of action for the health benefits of probiotic bacteria is the gut. The intestinal 
mucosa forms a barrier between the external and internal environment of the human body. The 
gastrointestinal tract represents a complex ecosystem in which a balance exists between the 
intestinal microbiota and the host. It has been estimated that bacteria account for 35–50% of the 
volume content of the human colon (Vanhoutte et al., 2004; Ley et al., 2006). The microbiota 
mainly consists of facultative anaerobes and obligate anaerobes. Approximately 95% of the 
intestinal bacterial population in humans is comprised of obligate anaerobes, including 
Bifidobacterium, Clostridium, Eubacterium, Fusobacterium, Peptococcus, Peptostreptococcus and 
Bacteroides. 1–10% of the intestinal population is comprised of facultative anaerobes, including 
Lactobacillus, Escherichia coli, Klebsiella, Streptococcus, Staphylococcus and Bacillus (Guarner and 
Malagelada, 2003).  
The intestinal microbiota can be identified as an active “organ” with the gastro-intestinal tract 
serving as a large mucosal surface that bridges the gap between inside outside the body. Along 
this mucosal interface, microbes and foreign antigens colonizing or passing through the gastro-
intestinal tract interact with important components of the immune system. The microbiota is 
involved in different processes, such as the improvement of nutrient bioavailability and 
degradation of non-digestible dietary compounds, the supply of new nutrients, and the removal 
of harmful, toxic and non-nutritional compounds. The main positive functions of the microbiota 
on the host organism are the following: participation in the defence system of the intestinal 
mucosa, resistance to colonisation of pathogens (Cummings and Macfarlane, 1997), production of 
short chain fatty acids, metabolites that play important physiological functions in fermentation 
(Resta, 2009), production of vitamins, especially vitamins B and K (Lanning et al., 2005), 
interactions with the mucosal immune system (Tsuji et al., 2008), and degradation of xenobiotics 
(Reiff et al., 2009). Alteration of the microbiota of the intestine, such as during antibiotic use, 
disease and aging, can negatively affect the beneficial role of the microbiota. 
1.10 Probiotic bacteria 
Elie Metchnikoff, the Nobel Prize winner for the discovery of phagocytosis, proposed a scientific 
basis for the beneficial effects of bacteria in yoghurt at the start of the 20
th
 century by attributing 
the long life of Bulgarian peasants to their consumption of fermented milk containing lactic acid 
bacteria (Metchnikoff, 1907). He suggested that usage of fermented milk would decrease toxic 
microbial activity in the colon. 
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Probiotics were earlier defined by Fuller (1991) as “live microbial food supplements which 
beneficially affect the host either directly or indirectly by improving its intestinal microbial 
balance”. Today, the most commonly accepted definition states that probiotics are “live microbial 
food supplements which, when given in adequate amounts have a demonstrated beneficial effect 
on human health” (WHO, 2002). In order to be effective the probiotic micro-organisms must be 
able to survive the digestive conditions, including bile acids, and they must be able to colonise the 
gastrointestinal tract at least temporarily without any harm to the host (FAO/WHO, 2002). Only 
certain strains of micro-organisms have these properties. Most probiotic micro-organisms are 
members of two bacterial genera, Lactobacillus and Bifidobacterium (Saxelin et al., 2005), but 
they can also belong to yeasts, especially Saccharomyces, or enterococci (Shortt, 1999). In 
probiotic foods the number of these beneficial bacteria is increased and maintained at a high 
level. Among the most common probiotic microbes are strains of Lactobacillus (L.) acidophilus and 
Bifidobacterium (B.) animalis subsp. lactis. 
There are several criteria for a probiotic bacterium, including being able to exert proven beneficial 
effects on the host, being non-pathogenic and non-toxic, being present as living cells, being able 
to survive the passage through the gut and resistance against metabolic enzymes and being stable 
and remain viable through storage (Pathmakanthan et al., 2000). Many probiotic organisms 
originate in fermented foods, and they have a long history of safe use in human consumption. The 
International Dairy Federation has prepared a list of safe microorganisms with a documented 
history of use in food (IDF, 2002). The list was recently updated and reflects advances in 
fermented food, microbial culture technology and knowledge, including probiotics (IDF, 2011). 
Today the most important classification systems are the Qualified Presumption of Safety (QPS) in 
Europe (EFSA, 2010) and the generally recognised as safe (GRAS) status and notification system in 
the United States (Food and Drug Administration, U.S.). These systems largely define which 
bacteria can be used as safe probiotics.  
When discussing probiotic bacteria, the term lactic acid bacterium is often used. Lactic acid 
bacteria are a heterogeneous group of Gram-positive, non-sporing cocci or rods, which produce 
lactic acid as the major end-product of carbohydrate fermentation. Lactic acid bacteria comprise 
strains from the genera Aerococcus, Alliococcus, Carnobacterium, Enterococcus, Lactobacillus, 
Lactococcus, Lactoshaera, Leuconostoc, Oenococcus, Pediococcus, Streptococcus, 
Tetragenococcus, Vagococcus and Weissella (Masood et al., 2011). Lactic acid bacteria used as 
probiotics only include strains from the genus Lactobacillus (Table 1.4). 
The genus Bifidobacterium is often considered in the same context as lactic acid bacteria, but is 
phylogenetically unrelated to them. Bifidobacteria have a unique mode of sugar fermentation. 
The genus Propionibacterium is of special interest in food production with several strains being 
used as dairy starters to produce flavour compounds, carbon dioxide and propionic acid, a 
preserving agent (Ouwehand, 2004). In recent studies Propionibacterium freudenreichii has also 
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been shown to have probiotic properties (Ouwehand, 2004). Furthermore, some other bacteria, 
yeast and moulds are described as probiotics (Goldin, 1998). 
There are several important modes of action for probiotic bacteria, including modification of gut 
pH, colonisation ability, inhibition of the colonisation, adhesion and invasion of pathogens, direct 
antimicrobial effect, replacement of already adhered pathogens, competing for available 
nutrients and growth factors, regulation of the immune system of the host, normalisation of the 
gut microbiota, and different metabolic effects (reviewed in Salminen et al., 1998; Andersson et 
al., 2001). It is essential that the probiotic bacteria retain viability during processing and transit 
through the gastrointestinal tract. The beneficial effects of consumption of probiotic bacteria 
include improving intestinal tract health, enhancing the immune system, and synthesizing and 
enhancing the bioavailability of nutrients. Probiotics have well-documented health effects in the 
alleviation of symptoms of lactose intolerance, reduction in the risk of allergies and acute 
gastroenteritis (rotavirus, antibiotic-associated and travellers’ diarrhoea), and improving bowel 
regularity at times of constipation and inflammatory bowel disorders (Crohn's disease and 
ulcerative colitis) (Fooks and Gibson, 2002; Tuohy et al., 2003; Saxelin et al., 2005; Sazawal et al., 
2006) (discussed in section 1.11).  
1.10.1 Lactobacilli 
Lactobacilli are normal inhabitants of the human intestine and vagina. Lactobacilli are Gram-
positive facultative anaerobes. They are non-spore forming and non-flagellated rod or 
coccobacilli. They are either aerotolerant or anaerobic and strictly fermentative. In strictly 
fermentative bacteria, glucose is fermented predominantly to lactic acid. Lactobacilli are classified 
as lactic acid bacteria. Lactobacilli used as probiotics include L. acidophilus, L. brevis, L. bulgaricus, 
L. casei, L.cellobiosus, L. crispatus, L. curvatus, L. fermentum, L. gasseri, L. johnsonii, L. plantarum, 
L. rhamnosus and L. salivarus. Lactobacilli common in the food industry belong to the European 
QPS status organisms, which can be used in foods and feeds. 
L. plantarum strains used in some studies of this thesis have been isolated from traditionally 
fermented dadih. Dadih, a yogurt-like product, is an Indonesian traditional fermented product 
from West Sumatra, which is spontaneously fermented from fresh raw buffalo milk in bamboo 
tubes and capped with banana leaves (Akuzawa and Surono, 2002). Different bacteria, mainly 
lactobacilli (L. plantarum, L. casei, and others), enterococci (E. faecium), and some pediococci can 
be found in the fermented dadih product (Surono and Hosono, 1996; Surono, 2003). L. plantarum 
is a versatile species present in a range of environmental niches including dairy, meat, and 
vegetable fermentations (de Vries et al., 2006). Studies on potential probiotic properties of 
indigenous lactic acid bacteria isolated from dadih have demonstrated antimutagenic, mutagen-
binding, and cholesterol-binding properties, as well as acid and bile tolerance, good adhesion 
properties, and antipathogenic properties (Surono, 2003; Pato et al., 2004; Dharmawan et al., 
2006; Collado et al., 2007a and 2007b). 
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1.10.2 Bifidobacteria 
Bifidobacteria are normal inhabitants of the human and animal colon. Newborns, especially 
breast-fed, are colonised with bifidobacteria within days after birth (Fuller, 1991). Bifidobacteria 
were first isolated from the faeces of breast-fed infants. In general, bifidobacteria form the 
hallmark of the microbiota of a healthy breastfed infant, and bifidobacteria may constitute over 
half of the intestinal bacteria at this age. The population of these bacteria in the colon appears to 
be relatively stable until advanced age when it appears to decline (Gueimonde et al., 2010). The 
bifidobacteria population is influenced by a number of factors, including diet, antibiotics and 
stress (Turroni et al., 2011). Bifidobacteria are Gram-positive anaerobes. They are non-motile, 
non-spore forming and catalase-negative. They are saccharolytic organisms that produce acetic 
acid and lactic acid without generation of CO2, except during degradation of gluconate. 
Bifidobacteria used as probiotics include B. adolescentis, B. animalis, B. bifidum, B. breve, B. 
infantis, B. longum, and B. thermophilum (Goldin, 1998; Salminen et al., 2004).  
 
Table 1.4. Examples of bacterial species used as probiotics 
Lactobacillus Bifidobacterium Enterococcus Other bacteria 
L. acidophilus B. adolescentis E. faecalis Bacillus cereus 
L. casei B. animalis (B. lactis) E. faecium Bacillus subtilis 
L. fermentum B. bifidum  Escherichia coli 
L. gasseri B. breve  Clostridium butyricum 
L. johnsonii B. longum  Lactococcus lactis 
L. paracasei 
L. plantarum 
B. thermophilum  Propionibacterium freudenreichii ssp. 
Shermanii  
L. reuteri    Saccharomyces cerevisiae 
L. rhamnosus   Streptococcus salivarius  
L. salivarius   Streptococcus thermophilus 
based on Donohue and Salminen, 1996; Shortt, 1999 
 
1.10.3 Functional foods 
Functional foods have become an important and rapidly expanding area of the food development 
by promoting the health benefits provided by functional ingredients in the food products. 
Functional foods are targeted to improve the balance and activity of the gastrointestinal tract, 
specific targets including gastrointestinal functions, such as bowel habits, mucosal motility and 
modulating epithelial cell proliferation. Furthermore, functional foods target gastrointestinal 
functions that are associated with a balanced colonic microbiota, control of nutrient 
bioavailability, modification of gastrointestinal immune activity, and functions that are mediated 
by the endocrine activity of the gastrointestinal system. A functional food can be defined as a 
food containing a component that affects one or a limited number of functions in the body, which 
have positive effects on health, or if it has a physiological or psychological effect beyond the 
traditional nutritional effect (Bellisle et al., 1998). The European Union has set up regulations for 
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foods with approved health claims (European Union regulation on nutrition and health claims, 
2006), in which the same rules for the use of such claims in advertisements, labelling and 
presentation of foods, including food supplements, are implemented throughout the European 
Union. 
Probiotics and prebiotics are available commercially in many forms, such as 
foods, dietary supplements, and clinical therapeutic agents with oral or non-oral 
delivery. At present, probiotics are extensively consumed as fermented dairy products, such as 
yogurt or freeze-dried cultures. To be effective, probiotics must be capable of being prepared in 
an economically viable manner and on large scale, and during use and storage the probiotic 
should remain viable and stable. Maintaining the viability, stability, and functionality of probiotics 
during processing, formulation and storage is important for delivery of the health benefits 
(Saarela et al., 2002). An important area of research today is enhancing the stability of probiotics 
in industrial processes and keeping the probiotic properties intact during growth, harvest and 
storage (Tuomola et al., 2001; Grześkowiak et al., 2011). 
1.10.4 Selection criteria for probiotics 
The guidelines for the selection of probiotic strains for food use have been established by the FAO 
and the WHO expert consultation group (FAO/WHO, 2002). According to the guidelines the 
probiotic strain should be identified by genotypic and phenotypic methods as current knowledge 
suggests that probiotic effects are strain specific. Thereafter, functional characterisation, efficacy 
and safety tests should be performed with in vitro assays and, when appropriate, in animal 
studies. Most commonly used in vitro tests include ability to reduce pathogen adhesion to 
surfaces, resistance to gastric acid and bile acid, persistence in the gastrointestinal tract and 
antimicrobial activity against potentially pathogenic bacteria (Dunne et al., 1999; FAO/WHO, 
2002). Next, new probiotic strains are tested by using standard methods in two clinical 
evaluations; phase 1 (safety assessment) and phase 2 (efficacy assessment) studies. The safety 
assessment does not concern strains already on the IDF safety list (IDF, 2002). It is also 
recommended that human trials are repeated by more than one centre in order to confirm the 
results. Finally, the guidelines also provide recommendations for the labelling of probiotic food 
products, such as contents, numbers of viable bacteria, end of shelf-life and proper storage 
conditions. 
In general, for microorganisms to be considered as probiotics, they should be isolated from the 
same species as the intended host; have a demonstrable beneficial effect on the host; be non-
pathogenic, non-toxic, and free of significant adverse side effects; be able to survive through the 
gastrointestinal tract; be stable during the intended product shelf life and contain an adequate 
number of viable cells to confer the health benefit; be compatible with product format to 
maintain desired sensory properties; and labelled accurately (reviewed in Collado et al., 2009). 
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1.10.5 Safety assessment of probiotics 
The use of lactic acid bacteria and bifidobacteria as probiotics requires a safety assessment. The 
functional properties of the strains should be well studied and documented. Probiotics belonging 
to the genera Lactobacillus and Bifidobacterium have a good safety status as they are present in 
the normal intestinal microbiota of humans and have a long history of safe use in fermented foods 
(Tuohy et al., 2003). Species from other bacterial genera such as Streptococcus, Bacillus, and 
Enterococcus have also been used as probiotics, but there are concerns surrounding the safety of 
such probiotics because these genera also contain pathogenic species. Enterococci can be 
associated with nosocomial infections and may have antibiotic resistance (Mundy et al., 2000). 
Infections caused by probiotic bacteria other than enterococci are quite rare and usually originate 
from the body’s indigenous microbiota rather than from ingested food. The patients have often 
had a reduced immune function or underlying diseases (Adams, 1999). Boyle et al. have reviewed 
the safety of probiotics and discussed areas of uncertainty regarding their use, including reported 
cases of sepsis related to probiotic use (2006). 
Proper taxonomic identification of the probiotic is the starting point for safety as well as efficacy 
assessment (FAO/WHO, 2002). When considering the safety of probiotics, the side effects that 
theoretically could occur include systemic infections, deleterious metabolic activities, excessive 
immune stimulation in susceptible individuals and gene transfer (Marteau, 2001). Probiotics 
should be characterised by determining at least the infectivity in immunocompromised animal 
models, harmful metabolic activity, toxin production, hemolytic activity, antibiotic resistance, side 
effects in humans and adverse incidents in consumers (FAO/WHO, 2002). In Europe, the safety 
assessment is based on the EFSA QPS-system, which continuously evaluates the safety data on 
microbes added into foods and feeds (EFSA, 2010). 
1.11 Beneficial health effects of probiotic bacteria 
The literature available on the potential of probiotic bacteria in the treatment of different 
infections and disorders and on proven health effects is extensive. Only some of the reported 
beneficial health effects are presented in this section. 
Probiotics have been linked with a range of beneficial effects on human health, both well-
documented and less studied suggested health effects. It should therefore be remembered that 
there is a major difference between a proposed and a well-established health effect. Probiotics 
have well-documented health effects in the alleviation of symptoms of lactose intolerance, 
reduction in the risk of allergies and acute gastro-enteritis (rotavirus, antibiotic-associated and 
travellers’ diarrhoea), constipation, inflammatory bowel disorders (Crohn's disease and ulcerative 
colitis), and necrotizing enterocolitis (reviewed in Ouwehand et al., 2002; Parvez et al., 2006; 
Masood et al., 2011).  Several proposed health effects of probiotic bacteria have also been 
reported, including adjuvant therapy in Helicobacter pylori eradication (Tong et al., 2007), 
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enhancement of the adaptive immune response, treatment or prevention of urogenital and 
respiratory tract infections, and prevention or alleviation of allergies and atopic diseases in infants 
(Tuohy et al., 2003; Saxelin et al., 2005). Positive results on the effects of probiotics on the 
respiratory system have also been obtained, especially in preventing and reducing the severity of 
respiratory infections (Perdigon et al., 1999). 
Generally, health benefits of probiotics have often been characterised using single bacterial 
strains, and therefore the proven effects can only be defined for the specific strain studied 
(Salminen et al., 2004). One of the most studied clinical uses of probiotics in humans is in the 
management of diarrhoeal diseases (reviewed recently in Hickson, 2011). This group of diseases 
includes antibiotic-associated diarrhoea and infective diarrhoea, such as rotavirus diarrhoea 
(Casas and Dobrogosz, 2000), or traveller’s diarrhoea in both adults and children (Pathmakanthan 
et al., 2000; Boyle et al., 2006; Allen et al., 2010). Several Cochrane-reviews have also analysed 
and reported the effect of probiotics in diarrhoeal diseases (e.g. Johnston et al., 2007; Allen et al., 
2010). The beneficial effect of probiotics on rotavirus infection is explained by the stabilizing 
effect of probiotics on the microbiota and the reduction of increased gut permeability caused by 
the infection (Isolauri, 2001). Potentially also inactivation or binding of viruses maybe involved 
(Salminen et al., 2010). Antibiotic-associated diarrhoea results from an imbalance in the colonic 
microbiota caused by antibiotic therapy. Microbiota alteration changes carbohydrate metabolism 
with decreased absorption of short-chain fatty acids and an osmotic diarrhoea as a result. Another 
consequence is overgrowth of potentially pathogenic organisms, such as Clostridium difficile 
(Parkes et al., 2009). The Cochrane Group produced a systematic review (Pillai and Nelson, 2008) 
to evaluate the evidence for the treatment of Clostridium difficile-associated diarrhoea. The 
authors concluded that there was insufficient evidence to support the use of probiotic therapy as 
an addition to antibiotic therapy, and no evidence for the use of probiotics alone, in the treatment 
of Clostridium difficile colitis. 
Clinical intervention studies have shown that specific probiotic strains may also be able to shorten 
the duration or reduce the risk of certain viral infections. One example is the shortening the 
duration of viral diarrhoea, and reducing the risk of viral diarrhoea especially in infants and 
children (Isolauri et al., 1991). Moreover, selected probiotics have been effective also against 
respiratory tract infections of viral origin (Hatakka et al., 2001; Cobo Sanz et al., 2006). 
Probiotic treatment might alleviate the side effects of antibiotics and reduce the incidence and 
severity of antibiotic-associated diarrhoea as indicated in several reports (D’Souza et al., 2002; 
Sazawal et al., 2006; Szajewska et al., 2006). For example, treatment with probiotics including L. 
rhamnosus may reduce the risk of antibiotic-associated diarrhoea, improve stool consistency 
during antibiotic therapy, and enhance the immune response after vaccination (D’Souza et al., 
2002). Probiotics appear to be most effective in the prevention and treatment of rotavirus and 
antibiotic-associated diarrhoea, while the effect on travellers’ diarrhoea needs further 
assessment. 
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The effect of probiotic bacteria to alleviate symptoms of lactose intolerance and of food allergies 
in infants (reviewed in Salminen et al., 2004; Aureli et al., 2011; Masood et al., 2011) is well 
established. Several studies have focused on immunomodulation by probiotic treatment, and 
many potential benefits are discussed, such as stimulation of non-specific intestinal immune 
reactions with bifidobacteria (Casas and Dobrogosz, 2000) and prevention of the development of 
atopic disease (Kalliomäki et al., 2001). The role of probiotics in the recurrence of allergic 
respiratory symptoms in children was recently studied by assessing whether a daily, long-term (12 
months) consumption of a probiotic containing fermented milk could improve and modify the 
immunological profile of children with allergic symptoms (Giovannini et al., 2007). The study 
showed that probiotics supplementation reduced the recurrence of yearly rhinitis and lowered 
the incidence of allergic rhinitis in the children. 
The potential of probiotics to decrease serum cholesterol has been investigated. It has been 
concluded that evidence of hypocholesterolemic effects is available in vitro and in vivo in animals, 
possibly via deconjugating bile and increasing faecal excretion of bile acids (Casas and Dobrogosz, 
2000; Lichtenstein and Goldin, 2004). Animal studies have demonstrated the efficacy of a range of 
probiotic bacteria to be able to lower serum cholesterol levels (Sanders, 2000). Human studies 
have showed conflicting results, some studies indicating that probiotic bacteria may reduce serum 
LDL-cholesterol levels (reviewed in Ooi and Liong, 2010), while in other studies no such effect has 
been observed (de Roos et al., 1999).  
Probiotic supplementation has also been shown to be effective for alleviation of lactose 
intolerance symptoms in adults. As lactic acid bacteria actively convert lactose into lactic acid, 
ingestion of specific strains with high lactase activity may help lactose intolerant individuals 
tolerate dairy products (Sanders, 2000). Not all probiotic strains are able to ferment lactose or 
alleviate lactose intolerance, and lactase production is also strain dependent. 
Helicobacteri pylori is a Gram-negative spiral-shaped, micro-aerophilic rod colonizing the human 
gastric mucosa and causing peptic ulcers. Probiotic bacteria may affect Helicobacter pylori 
infections by eradication of the infection when used in combination with standard medical 
treatments. At the moment there is no standard in medical practice or regulatory approval for 
such treatment (Hamilton-Miller, 2003; Myllyluoma et al., 2005). 
Irritable bowel syndrome (IBS) is characterised by abdominal pain, bloating, and change in bowel 
habit, with an absence of any clear mucosal abnormality. Probiotics may be of benefit in 
managing the symptoms of IBS via a number of mechanisms, such as increasing mucosal 
interleukins and reducing pro-inflammatory cytokines. Different studies in adults have showed 
that B. infantis, L. rhamnosus GG, and a mixture of probiotics (L. rhamnosus GG, L. rhamnosus LC-
705, B. breve Bb99 and Propionibacterium freudenreichii JS) can be effective in alleviating 
symptoms of IBS (Kajander et al., 2005 and 2008). 
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Inflammatory bowel disease (IBD) is a chronic and recurrent inflammation generally affecting the 
colon or the small intestine and includes ulcerative colitis, pouchitis, and Crohn's disease. The use 
of probiotics in the treatment of IBD has been assessed (Gionchetti et al., 2002; Marteau, 2006). 
The best results so far have been obtained on ulcerative colitis and chronic pouchitis (Gionchetti 
et al., 2002). 
Many studies have been aimed at explaining the mechanisms through which probiotics 
beneficially affect human health. Strengthening of the gut mucosal barrier could be one of the 
mechanisms involved. A large part of the microorganisms in the human gut are non-culturable 
using current methodology. However, these bacteria are active in the gut demonstrating that 
viability is not always a requirement for such health benefits; also non-viable probiotics have been 
demonstrated to have health benefits. Adhesion abilities of beneficial bacteria have been widely 
studied (Tuomola et al., 2000). Adhesion to the intestinal mucosa, followed by at least transient 
colonization is considered important for probiotic bacteria to exert their favourable effects as it 
prolongs the contact period with the host, thus allowing more time for the probiotics to exert 
their beneficial health effects. Even among different lactobacilli, adhesion properties vary, and 
different possible binding sites including proteins, carbohydrates, or a combination of both are 
suggested in the literature (Rojas and Conway, 1996; Alander et al., 1999; Tuomola et al., 2000; 
Rojas et al., 2002). Current data support the hypothesis that the use of probiotic combinations 
selected for specific targets may have a major impact on human health (Collado et al., 2007c; 
Collado et al., 2008). 
1.12 Removal of different contaminants by probiotic bacteria 
Previous studies have shown the effect of probiotic bacteria in the removal of different 
contaminants, such as heavy metals and mycotoxins. Also the removal of Shiga toxin has been 
assessed. The most efficient microbial species and strains in the removal of these compounds vary 
between contaminants tested. In a pilot study investigating the removal of cyanotoxins (Meriluoto 
et al., 2005) it was reported that three probiotic strains, L. rhamnosus GG, L. rhamnosus LC-705 
and B. lactis Bb12, were able to remove MC-LR from solution. The highest removal in that study 
was observed with heat-treated bacteria, but further investigation (shown in the result part of 
this thesis) concluded that heat-treated bacteria were in fact inefficient in microcystin-removal.  
Possible ways of interaction of probiotics with different contaminants, such as toxins and viruses, 
are illustrated in Fig. 1.5. Some of the studies and the characterisation of probiotics and their 
specific interactions with potentially pathogenic bacteria, bacterial toxins, fungal toxins and heavy 
metals are described in this section. 
1.12.1 Mycotoxins 
Previous studies have shown that specific strains of probiotic bacteria are able to bind the 
mycotoxins ochratoxin A (Turbic et al., 2002) and aflatoxins B1 (AFB1) (El-Nezami et al., 1998a; 
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Peltonen et al., 2001) and M1 (Pierides et al., 2000). Many of these studies have involved 
Lactobacillus strains, and physical binding has been proposed as one mechanism of toxin removal. 
Acid and heat treatment of the probiotics had varying effects on binding properties, but often 
caused increased toxin binding (Haskard et al., 2000 and 2001). 
Several bacterial strains have been tested for their ability to bind aflatoxins and other mycotoxins 
to their surface. Five strains of probiotic Lactobacillus and one Propionibacterium were shown to 
be more efficient in aflatoxin-removal than Escherichia coli (El-Nezami et al., 1998a). Among the 
five strains, L. rhamnosus strains GG and LC-705 appeared to be most efficient in AFB1-removal, 
removing approximately 80% of AFB1 within minutes of incubation. These two strains were later 
confirmed as the most efficient strains in AFB1-removal among nine stains of Lactobacillus 
(Haskard et al., 2001). Peltonen et al. (2001) also studied a range of lactobacilli and bifidobacteria 
and found differences in AFB1-binding abilities between the studied strains. Also the bacterial 
concentration was shown to influence the AFB1-removal.  
Chemical and physical treatments of the probiotic bacteria affected their AFB1-removal ability. 
Heat and acid treatment enhanced AFB1-binding by L. rhamnosus GG and LC-705 (El-Nezami et al., 
1998a and 1998b). In another study, viable strains of bifidobacteria were shown to bind 4–56% 
while heat-treated bacteria bound 12–82% of the AFB1 (Peltonen et al., 2001). As heat-treated 
bacteria were more efficient in AFB1-removal than viable cells, metabolic degradation was not 
considered the mechanism responsible for AFB1-removal. It was therefore suggested that the 
toxin is bound to the bacterial surface.  
Besides in vitro studies the binding ability of three probiotic strains was tested ex vivo in the 
intestinal lumen of chicks (El-Nezami et al., 2000). The study reported that strains removed 36–
54% of the AFB1 from the soluble fraction of the luminal fluid within one minute. These results 
imply that bacterial AFB1 binding also appears under physiological conditions in the animal. 
Also two Fusarium mycotoxins, zearalenone and its derivative α-zearalenol have been shown to 
be removed by strains of Lactobacillus (El-Nezami et al., 2002) similarly to the removal of AFB1. 
1.12.2 Shiga toxin 
The anti-infectious activity of probiotic bifidobacteria against Shiga toxin-producing Escherichia 
coli has been examined in a fatal mouse infection model. Specific strains of bifidobacteria were 
shown to have an anti-infectious activity against Shiga toxin in the mouse model (Asahara et al., 
2004). The important features of the mechanism responsible for the anti-infectious activity of 
bifidobacteria were inhibition of Shiga toxin production, while bacterial growth was not affected, 
and improvement of intestinal environmental factors, such as pH and acetate concentration. The 
pathogenicity observed in the infected controls was noticeably inhibited in the group colonised by 
bifidobacteria. A strain of B. breve was shown to have the anti-infectious activity, while strains of 
B. bifidum and B. catenulatum were inefficient (Asahara et al., 2004). 
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1.12.3 Heavy metals 
Cadmium and lead are highly toxic heavy metals. Unlike many other toxic compounds, they are 
not degradable and tend to accumulate in exposed organisms. The removal process of heavy 
metals, such as cadmium, lead and arsenic, has been studied in different strains of probiotic 
bacteria (Halttunen et al., 2007a and 2007b). In addition, the possible mechanisms involved in the 
removal of cadmium and lead by lactic acid bacteria from water was investigated. Also the effect 
of other metals, reversibility of binding and recyclability of the biomass was assessed. 
Specific lactic acid bacteria were observed to have a strain-specific capacity to bind cadmium and 
lead from water. Based on the maximum binding capacity, the most efficient strains for cadmium 
and lead removal were B. longum 46 and L. fermentum ME3 (Halttunen et al., 2007a). Up to 99% 
of cadmium and 97% of lead were removed from solutions with initial metal concentrations of 
100 and 1000 μg/L, respectively, within minutes of incubation. In addition, the removal of arsenic 
was studied. After chemical modification, L. casei DSM20011 was shown to remove anionic 
arsenic (Halttunen et al., 2007b). The removal of arsenic, cadmium and lead was a rapid, pH-
dependent and reversible surface process. Ion exchange was reported to be among the 
mechanisms behind cadmium and lead binding by lactic acid bacteria (Halttunen et al., 2007a). 
This conclusion was supported by the reduced cadmium and lead removal in the presence of 
other cationic metals. Efficient desorption of cadmium and lead from the bacterial cells was 
achieved, although often more than one wash was needed to reach full desorption. 
1.12.4 Probiotic pathogen interactions 
The protective role of probiotic bacteria against gastrointestinal pathogens as well as the 
mechanisms responsible have been studied, as such interactions have been a criterion for 
selecting new probiotics for human use. The mechanisms by which probiotics exert their 
beneficial effects on the host are largely unknown. Among the identified mechanisms are the 
reduction of luminal pH, competition with pathogens for adhesion sites and nutritional sources, 
secretion of antimicrobial substances, toxin inactivation, and immune stimulation (Fooks et al., 
1999; Servin, 2004). Host-bacteria interaction mechanisms include physical bacteria-epithelium 
interaction, such as adhesion to mucosal and epithelial cells, stimulation of mucus secretion, 
production of defensive molecules, and support of gut barrier function. The bacteria-immune 
system interaction includes modulation and regulation of immune responses. Mechanisms of 
interactions between bacteria are exclusion and inhibition of pathogens by prevention of 
adhesion, secretion of antimicrobial substances, competition for nutrients and anti-toxin effects 
(Collado et al., 2009). 
Several studies suggest that combinations of specific probiotics strains may prove more effective 
than a single probiotic strain depending on the specific target. Combinations of known probiotic 
strains, such as L. rhamnosus GG and B. lactis Bb12, may have an improved impact on the 
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pathogen adhesion inhibition (Ouwehand et al., 2000; Collado et al., 2007d). Probiotic strains and 
their combinations were able to inhibit significantly the adhesion of Bacteroides vulgatus, 
Clostridium difficile, Staphylococcus aureus and Cronobacter sakazakii (Collado et al., 2007d). 
Specific probiotic combinations were demonstrated to be more efficient in the inhibition of 
pathogen adhesion and they were able to enhance the inhibition percentages compared to when 
the probiotic strains were tested alone.  
 
 
 
Figure 1.5. Interaction of probiotics with toxins and viruses in the human gut (modified from 
Salminen et al., 2010).  
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2. AIMS OF THE STUDY 
The aims of this research work have been to characterise the potential of probiotic lactic acid 
bacteria and bifidobacteria in removal of the cyanobacterial peptide toxins microcystins and 
cytotoxin cylindrospermopsin from aqueous solutions. Different physiological conditions 
potentially affecting the removal efficiency were tested. These included the effect of pH, 
temperature, toxin concentration, bacterial cell density and cell viability (publications I and II). The 
cell viability and the impact of glucose as a source of energy were then studied more in detail 
(publication III). Furthermore, the location and mechanism of microcystin removal was 
investigated by studying a possible extracellular enzymatic degradation of microcystins and the 
degradation pathway was compared to other microcystin-degrading bacteria (publication IV).  
Consequently, the specific aims of this study were to: 
 Characterise the capacity of specific strains of probiotic lactobacilli and bifidobacteria to 
remove different cyanobacterial toxins from aqueous solutions and choose a number of 
specific strains optimal for cyanotoxin removal (I) 
 Evaluate the potential of specific probiotic bacteria for decontamination of cyanotoxin-
containing water (II) 
 Assess factors and different conditions optimal for toxin removal (I–III) 
 Investigate the nature of the removal process (III, IV) 
 Investigate the hypothesis of extracellular enzymatic degradation of microcystins by 
probiotic bacteria (IV) 
 Compare the degradation pathway of previously identified microcystin-degrading 
bacteria with the probiotic strains to identify the possible toxin-removal mechanism of 
probiotic bacteria (IV) 
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3. EXPERIMENTAL PROCEDURES 
3.1 Chemicals 
Methanol (HPLC-grade) and acetonitrile (HPLC S-grade) were from Rathburn (Walkerburn, UK). 
Formic acid (analytical-reagent grade) was from Riedel-de Haën (Seelze, Germany), trifluoroacetic 
acid (TFA) was from Fluka (Buchs, Switzerland) and hydrochloric acid (HCl) was from J.T. Baker 
(Deventer, the Netherlands). Water was purified to 18.2 Mcm on a Milli-Q Synthesis system 
(Millipore, Molsheim, France). MC-LR test solutions were prepared in 0.01 M phosphate-buffered 
saline (PBS; pH 7) (chemicals from Merck, Darmstadt, Germany) and glucose was from J.T. Baker 
(Deventer, The Netherlands). Scintillation liquid OptiPhase HiSafe 3 was from PerkinElmer (USA). 
Ethylenediamine tetraacetic acid (EDTA), phenylmethanesulfonyl fluoride (PMSF), iodoacetic acid 
and a protease inhibitor cocktail (containing 4-(2-aminoethyl)benzenesulfonyl fluoride, pepstatin 
A, E-64, bestatin, and sodium EDTA) were obtained from Sigma-Aldrich (St. Louis, MO), and Suc–
Ala–Ala–Phe–AMC from Bachem (Torrance, CA). 
3.2 Cyanobacterial cultures 
Microcystis PCC 7820 (Institut Pasteur, Paris, France), Anabaena sp. 90 (originating from the 
culture collection of Prof. Kaarina Sivonen, University of Helsinki, Finland), Anabaena lapponica 
966 (Spoof et al., 2006) and Microcystis NIES-107 (National Institute for Environmental Studies, 
Tsukuba, Japan) were cultured in our laboratory. The strains were cultured in modified Z8 
medium (Meriluoto and Spoof, 2005c). In the medium for the Anabaena strains nitrogen-
containing compounds were omitted. The cyanobacterial cultures were cultivated in 1–5 litre 
flasks at room temperature and under continuous illumination (20 W POWER-GLO aquarium 
lamps). Agitation was performed by sparging with sterile-filtered air. After 3 weeks the 
cyanobacterial cells were harvested on Whatman (Maidstone, UK) GF/A filters and the filters were 
air-dried and stored at -20 °C until extraction. Microcystins were extracted and purified by Dr Lisa 
Spoof and docent Jussi Meriluoto according to Meriluoto and Spoof (2005b and 2005d). 
Toxins produced by Microcystis strain PCC 7820 have been reported to be MC-LR, -LY, -LW and -LF 
(Lawton et al., 1994). Toxins produced by Microcystis NIES-107 include 3-demethyl(dm)-MC-RR, 
MC-RR, MC-YR, 3-dm-MC-LR and MC-LR (Meriluoto et al., 2004). Anabaena sp. 90 produces dm-
MC-RR, MC-RR, dm-MC-LR and MC-LR (Rapala et al., 1997) and Anabaena lapponica 966 produces 
CYN (Spoof et al., 2006).  
3.3 Microcystins 
MC-LR and MC-LF were extracted from Microcystis PCC 7820 and MC-RR was extracted from 
Microcystis NIES-107. In some experiments MC-LR extracted from a culture of Anabaena sp. 90 
was used. The microcystins were purified by high-performance liquid chromatography (HPLC) as 
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described earlier (Meriluoto and Spoof, 2005d). 10 μg of microcystin was dissolved in 1 mL of PBS 
buffer, and appropriate dilutions were made. 
The cyanobacterial extracts studied were Microcystis NIES-107 and Microcystis PCC 7820. 
Microcystis NIES-107 extract contained 1.3 μg dm-MC-RR, 12.8 μg MC-RR, 2.4 μg MC-YR, and 6.5 
μg MC-LR per vial, which was diluted to appropriate concentrations. Microcystis PCC 7820 extract 
contained 10.8 μg MC-LR, 0.94 μg MC-LY, 3.14 μg MC-LW and 2.03 μg MC-LF. CYN was isolated 
from Cylindrospermopsis raciborskii strain CR3 and purified in Prof. G.A. Codd’s laboratory 
(University of Dundee, UK) according to Metcalf and Codd (2005). 
3.4 Probiotic bacterial strains and cultivation 
Eleven commercial bacterial strains were tested for their microcystin removal capacity: L. 
rhamnosus GG (ATCC 53103, Valio Ltd, Helsinki, Finland), L. rhamnosus LC-705 (Valio Ltd, Helsinki, 
Finland), L. casei Shirota (obtained from Yakult Singapore Pty. Ltd, Singapore via Prof. Y-K Lee, 
National University of Singapore, Singapore), L. fermentum ME3 (University of Tartu, Estonia), L. 
acidophilus NCFM, L. plantarum Lp-115, and L. salivarius Ls-33 (Danisco Inc., Madison), B. lactis 
420 and B. lactis HN019 (Danisco Deutschland Gmbh, Niebüll, Germany), B. longum 46 (DSM 
14583) (Laine et al., 2003) and B. lactis Bb12 (Chr Hansen Ltd, Hørsholm, Denmark). The bacteria 
were obtained in commercial lyophilised form. For assays with freshly grown bacteria, the 
bacteria were cultured in MRS broth (Oxoid, Hampshire, UK) (MRS supplemented with 0.05% w/v 
cysteine-HCl for bifidobacteria) for 18 h at 37 C, harvested by centrifugation (3200 × g, 4 C, 20 
min) and washed twice with PBS. The viability of the cells was tested on MRS agar plates. Viable 
counts were determined after incubation for 48 h at 37 C. Non-viable bacteria were prepared by 
95% ethanol treatment of the bacteria for 30 min, by 1 M HCl treatment for 30 min or by heat 
treatment for 30 min at 90 C. The bacteria were washed twice with PBS after the treatments. In 
some experiments the cells were suspended in PBS with or without glucose (1, 2, or 3%). Glucose 
was added in PBS as a bacterial nutrient. The cell density in all experiments was approximately 
10
10
 colony forming units (CFU)/mL. Total viable counts of bacterial suspensions were determined 
prior to incubation by flow cytometry (section 3.4.2). 
Two dadih lactic acid bacterial strains were tested for their microcystin-removal capacity. The 
indigenous dadih strains were L. plantarum strains with the identification numbers IS-10506 and 
IS-20506 (Gene Bank Accession numbers DQ860148 and DC860149, respectively) from the 
University of Turku culture collection. The culturing conditions were the same as for the 
commercial probiotic strains. 
3.4.1 Plate counts 
Viable counts (CFU/mL) were obtained by plate counting from bacterial suspensions after 0, 24, 
and 48 h of incubation in PBS containing 100 μg/L MC-LR. The bacterial suspensions were serially 
diluted in PBS buffer, and appropriate dilutions were spread on MRS agar plates (Oxoid) (MRS 
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agar supplemented with 0.05% w/v cysteine-HCl for bifidobacteria) and incubated for 48 h at 37 
°C (anaerobic conditions for bifidobacteria; 10% H2, 10% CO2, and 80% N2; Concept 400 anaerobic 
chamber, Ruskinn Technology, Leeds, UK). All plate counts were determined in three independent 
experiments, and each assay was performed in triplicate. 
3.4.2 Fluorescent counts 
Counts of total, viable, and dead bacteria were obtained by the use of LIVE/DEAD BacLight 
Bacterial Viability Stain Kit (Molecular Probes, Eugene, OR). The viability kit stain mixture, used for 
total counts of bacterial population, distinguished live bacterial cells from dead by means of 
membrane integrity and increased the efficiency of staining to indicate viability (Franks et al., 
1998). 
Bacterial cells were washed with PBS buffer, and 10 μL was mixed with 1.5 μL of a mixture of 
SYTO9 and propidium iodide (PI) (1:1), nucleic acid stains from a LIVE/DEAD BacLight. The samples 
were then vortexed and incubated in darkness for 15 min at room temperature according to the 
manufacturer’s instructions. Immediately prior to analysis, 10 μL of fluorospheres (Molecular 
Probes) was added to each sample to obtain the absolute bacterial cell count. 
Flow cytometric analysis was performed using a BD FACSCalibur flow cytometer (Becton, 
Dickinson and Co., U.S.) with an air-cooled argon ion laser (488 nm at 15 mW). This standard 
instrument was equipped with two light scatter detectors that measure forward (FSC) and side 
scatter (SSC) and two fluorescence detectors (FL1, 525 nm; FL3, 620 nm). Data were stored as list 
mode files and analysed off-line using the System II V.3 software (Beckman Coulter). Ideally, live 
bacteria with intact plasma membranes fluoresce green and the dead or injured cells with 
compromised membranes fluoresce red. In accordance with the manufacturer’s instructions, all 
green cells (SYTO9) were considered viable, and red cells (PI) were considered dead. Viability was 
determined in two independent experiments, and each assay was performed in duplicate. The 
percentages of viability were calculated comparing the total viable counts before incubation (t = 
0, 100% viability) with the viable cells labelled with SYTO9 (green colour) obtained after 24 and 48 
h of incubation at 4 and 37 °C with different concentrations of glucose. 
3.4.3 Microscopy 
Visual inspection of the viability of bacteria during incubation with MC-LR at 37 °C in absence or 
presence of glucose (0 or 1%) was determined by microscopy. An Olympus epifluorescence 
microscope BX50 (Olympus, Tokyo, Japan) with filter U-MWIB (excitation, 460–490 nm; emission, 
515–700 nm) was used. Images were recorded with a digital camera (model DP-10; Olympus, 
Hamburg, Germany): green bacteria, viable; red bacteria, non-viable. 
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3.5 Sphingomonas strains 
Sphingomonas ACM-3962 (Australian Collection of Microorganisms) and Sphingomonas B9 
(AB159609, Harada et al., 2004; Tsuji et al., 2006) were cultured in peptone-yeast extract medium 
and incubated for experiments for 18 h at 28 °C. The protocol for harvesting and washing the 
bacteria was the same as for the probiotic strains. 
3.6 Microcystin removal assay 
One millilitre of the freshly grown bacteria suspended in PBS at a concentration of approximately 
10
10
 CFU/mL with or without the addition of glucose (1, 2, or 3%) together with 100 μg/L MC-LR 
were incubated in 1.5 mL borosilicate glass chromatographic vials under continuous reciprocal 
shaking, 120 rotations per minute (Certomat WR, B. Braun, Melsungen, Germany) at different 
temperatures (4, 22 or 37 °C) for different times (0, 18, 24, and 48 h). Lyophilised bacteria were 
used at a concentration of 8.8 × 10
9
–2.7 × 10
10
 CFU/mL. Microcystin concentrations of 1, 10 and 
100 µg/L were used and CYN at a concentration of 100 µg/L. The microcystin concentrations in 
the experiments with the cyanobacterial extracts were 13 µg/L dm-MC-RR, 128 µg/L MC-RR, 24 
µg/L MC-YR, and 65 µg/L MC-LR in Microcystis NIES-107 and 108 µg/L MC-LR, 9.4 µg/L MC-LY, 31.4 
µg/L MC-LW, and 20.3 µg/L MC-LF in Microcystis PCC 7820. 
After incubation, 200 μL aliquots were taken and centrifuged (12000 × g, 10 min, room 
temperature) in 300 μL borosilicate glass chromatographic inserts. The supernatants were 
analysed to determine the residual MC-LR concentration by HPLC or ESI-LC-MS compared with a 
100 μg/L microcystin or CYN control in PBS. Each assay was carried out in triplicate. Appropriate 
microcystin controls without bacteria were also prepared and they showed no reduction of MC-LR 
during incubation. Plastics were avoided in the preparation of the aqueous microcystin solutions, 
as adsorption of the toxins on polypropylene surfaces is known to occur (Hyenstrand et al., 2001). 
The microcystin removal assay for the Sphingomonas strains ACM-3962 and B9 was performed as 
described above and the potential degradation products were studied and identified by HPLC-
DAD and LC-ESI-MS.  
3.7 Microcystin removal in the presence of bacterial cell extracts 
Bacterial cell extracts were prepared for three of the studied probiotic strains: L. rhamnosus GG, L. 
rhamnosus LC-705 and B. longum 46. 100 mL of 18 h old cultures were washed twice with PBS 
buffer (pH 7.0). Bacterial cell disruption was performed by ultrasonication on ice (Bandelin 
Sonopuls HD 2070 ultrasonic homogenizer, Bandelin Electronic, Germany), the success of 
sonication was checked by microscopy, cell debris was removed by centrifugation (12000 × g, 10 
min, 4 °C) and the supernatant was used for the MC-LR removal assays. MC-LR (final 
concentration 100 µg/L)
 
was incubated with 1.5 mL of cytosolic cell extract in 1.5 mL borosilicate 
glass chromatographic vials under continuous reciprocal shaking (120 rotations per minute, 
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Certomat WR, B. Braun). After 12, 18 and 24 h of incubation at 37 °C aliquots were taken, 
centrifuged and analysed on HPLC. 
3.8 Extraction of MC-LR from bacterial cells and analysis of toxins using ELISA 
After 24 h incubation with MC-LR at 37 °C cell suspensions of L. rhamnosus GG, L. rhamnosus LC-
705 and B. longum 46 were centrifuged (3200 × g, 20 min), the pellets were washed twice with 
PBS and the cells were resuspended in 75% MeOH. The cells were disrupted by ultrasonication 
(Bandelin Sonopuls HD 2070 ultrasonic homogenizer), centrifuged, and the residual MC-LR 
concentration was determined with an enzyme-linked immunosorbent assay (ELISA) QuantiPlate 
Kit for microcystins according to the manufacturer’s instructions (Envirologix, Portland, ME, USA). 
The amount of toxin found inside the cell pellet was compared with the amount of toxin removed 
during the 24 h incubation (HPLC results). 
3.9 Correlation of proteolytic activity and MC-LR removal ability in the absence or presence of 
glucose 
The bacterial cells of L. rhamnosus GG were suspended in PBS at a concentration of 10
10
 CFU/mL 
together with 100 µg/L MC-LR. Four experimental groups were performed (in triplicate): bacterial 
suspension with initial concentration of 1% (w/v) glucose and an extra 1% added at 3 h and 6 h 
(group A); bacterial suspension in PBS at the beginning and 1% glucose addition at 3 h and 6 h 
(group B); bacterial suspension in PBS and 1% glucose addition at 6 h (group C); bacterial cells 
incubated without glucose (group D). After successive time of incubation, 150 µL aliquots were 
taken to determine the residual MC-LR concentration by HPLC (section 3.14) and 100 µL of sample 
was used in an enzymatic assay. 
3.10 Removal of 
14
C-labelled MC-LR by probiotic bacteria 
Experiments with radiolabelled microcystins were carried out to investigate whether microcystin 
is transported into the bacterial cells during toxin removal. 
14
C-labelled MC-LR was purified from 
Microcystis PCC 7820, which was grown in 1-litre cultures in the presence of sodium 
14
C-
bicarbonate (50 mCi/mmol, Perkin Elmer Life Sciences, USA) according to Brooks and Codd (1987) 
and Craig et al. (1996). The specific activity of 
14
C-MC-LR was 13.4 µCi/mmol. 
14
C-MC-LR at a 
concentration of 1 µg/mL was incubated with the bacterial strain L. rhamnosus GG. After 24 h 
cells were centrifuged and bacterial cell disruption was performed by ultrasonication on ice 
(Bandelin Sonopuls HD 2070 ultrasonic homogenizer). Both the supernatant and cell extract was 
analysed for the presence of 
14
C (1216 Rackbeta Liquid Scintillation counter, Wallac, Finland). 
Simultaneously, the removal of MC-LR was monitored on HPLC and fractions were collected for 
determination of 
14
C-MC-LR bound to the cells or present in the supernatant. 
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3.11 Comparison of MC-LR removal and activity of cell wall-associated proteinases in the 
presence of proteinase inhibitors 
The activity of cell-associated proteinases of L. rhamnosus GG was measured after incubation with 
different concentrations of protease inhibitors. To check the type of proteinase, 18 h old culture 
of L. rhamnosus GG washed with PBS buffer (10
10
 CFU/mL) was incubated for 0.5h with different 
doses of typical inhibitors of metalloprotease (EDTA; 1, 5 and 10 mmol/L), serine protease (PMSF 
diluted in methanol; 0.5, 5 and 50 mmol/L) and cysteine protease (iodoacetic acid; 0.01, 0.05, 0.1, 
0.5 and 1 mmol/L). Additionally, a protease inhibitor cocktail containing 4-(2-
aminoethyl)benzenesulfonyl fluoride, pepstatin A, E-64, bestatin, and sodium EDTA with final 
concentrations of 2.32, 0.03, 0.2, 0.033 and 10 mmol/L, respectively, was used. To exclude the 
impact of the inhibitors on the viability of the bacterial cells traditional plate counting using MRS 
agar plates (section 3.4.1) was performed at the beginning of the experiment and after 6 h of 
incubation. Based on the results of this experiment, the involvement of EDTA in MC-LR removal 
was investigated in detail. A part of the sample was taken after 0, 2, 4 and 6 h to measure the 
proteolytic activity and the concentration of microcystin; assays were performed as described in 
3.13.  
3.12 Toxicity assay 
Toxicity of the MC-LR samples after incubation with cells of L. rhamnosus GG and L. rhamnosus LC-
705 was established by protein phosphatase 1 (PP1) inhibition assay as described by Meriluoto 
and Spoof (2005a). The concentration of MC-LR (standard) for preparing the calibration curve 
ranged between 0.125–4.0 µg/L. Part of the samples, which were analysed by HPLC and in 
enzymatic assays, were frozen and diluted directly before the experiment to obtain a MC-LR 
concentration between 0.5–2.0 µg/L. The toxicity values were converted to MC-LR equivalents.   
3.13 Enzyme assay 
The standard peptidase assay was performed at 37 °C with 0.02 µmol/L Suc–Ala–Ala–Phe–AMC in 
0.1 M Tris-HCl, pH 7.0 as a substrate and 25 µmol/L 7-amino-4-methyl-coumarin (AMC) dissolved 
in PBS as a standard. The density of cell suspension used in enzyme assays was approximately 10
10
 
CFU/mL. Appropriate dilutions of the AMC standard (12.5 µmol/L, 6.25 µmol/L and 2.5 µmol/L) 
were made fresh daily. 150 μL of substrate was added to 25 μL of sample or standard (n=3); 150 
μL of Tris buffer was added to 25 μL of cell suspension/extract and 150 μL of substrate with 25 μL 
of PBS was used as the blank. After 1 h of incubation at 37 °C the reaction was stopped by cooling 
to 0 °C. Finally, the fluorescence of the product (free AMC) was measured in the fluorescence 
plate reader Victor 1420 Multilabel counter (Wallac – PerkinElmer, Finland) at excitation/emission 
wavelengths of 365/442 nm and the activity was expressed in micromoles of substrate hydrolyzed 
within 1 h.  
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3.14 HPLC analysis 
MC-LR was quantified by HPLC on a Purospher STAR RP-18 endcapped column (55 mm × 4 mm, 3 
µm particles; Merck). The mobile phase consisted of a gradient of 0.05% aqueous TFA (solvent A) 
and 0.05% TFA in acetonitrile (solvent B) with the following linear gradient program: 0 min 25% B, 
5 min 70% B, 6 min 70% B, 6.1 min 25% B. The injection interval was 10 min, the injection volume 
was 30 μL, the flow rate was 1.0 mL/min and the column temperature 40 C. The HPLC-DAD 
system consisted of Merck-Hitachi (Darmstadt, Germany) La-Chrom series components: L-7612 
degasser, L-7100 quaternary gradient pump, L-7200 autosampler, L-7360 column oven, L-7450A 
diode-array UV detector operated at 238 nm and D-7000 interface. dm-MC-RR eluted at 3.0 min, 
MC-RR at 3.2 min, MC-YR at 3.7 min, MC-LR at 3.9 min, MC-LY at 4.9 min, MC-LW at 5.4 min, and 
MC-LF at 5.6 min.  
For experiments with 
14
C-MC-LR and MC-LR removal by Sphingomonas strains, a Purospher STAR 
RP-18 endcapped column (250 mm × 4 mm, 5 µm particles; Merck) was used. The mobile phase 
consisted of a gradient of 0.05% aqueous TFA (solvent A) and 0.05% TFA in acetonitrile (solvent B) 
with a linear gradient program (5–70% B over 40 min), injection interval 60 min. 
3.15 LC-MS analysis 
Analysis of samples with lower microcystin concentrations (1–10 µg/L) was performed on LC- ESI -
MS. The instrument consisted of an Agilent 1100 Series HPLC system (Agilent Technologies, 
Waldbronn, Germany) coupled to a Waters Micromass (Manchester, UK) Quattro Micro triple 
quadrupole mass spectrometer equipped with an electrospray interface. MC-LR was quantified on 
a Purospher STAR RP-18 endcapped column (30 mm × 4 mm, 3 μm particles; Merck). The mobile 
phase consisted of a gradient of 0.5% aqueous formic acid (solvent A) and acetonitrile (solvent B) 
with the following linear gradient program: 0 min 25% B, 10 min 70% B, 12 min 90% B, 13 min 
90% B, and 13.5 min 25% B. The injection interval was 20 min, the injection volume was 10 μL, the 
flow rate was 0.5mL/min and the column temperature was 40 C. The capillary voltage was set at 
3.8 kV and the cone voltage at 40 V (dm-MC-RR and MC-RR) or 75 V (rest of the microcystins). The 
desolvation gas (nitrogen) temperature and flow rate were set at 300 C and 650 L/h, 
respectively. The ion source temperature was set at 150 C. Ions were detected in the positive 
electrospray ionisation mode. Selected ion recording (SIR) was used in monitoring the following 
m/z: dm-MC-RR [M+2H]
2+
 512.7, MC-RR [M+2H]
 2+
 519.7, MC-LF [M+H]
+
 986.5 and [M+Na]
+
 
1008.5, MC-LR [M+H]
+
 995.5, MC-LY [M+H]
+
 1002.5, MC-LW [M+H]
+
 1025.5 and [M+Na]
+
 1047.5, 
MC-YR [M+H]
+
 1045.5.  Data acquisition was performed with MASSLYNX V4.0 software 
(Micromass). 
The mobile phase for CYN consisted of 0.1% formic acid in 1% methanol (solvent A) and 
acetonitrile (solvent B) with the following linear gradient program: 0 min 0% B, 5 min 0% B, 5.1 
min 70% B, 7.0 min 70% B, 7.1 min 0% B. The capillary voltage was set at 3.8 kV and the cone 
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voltage at 30 V. Ions were detected in the positive electrospray ionisation mode. SIR was used in 
monitoring m/z CYN [M+H]
+
 416.  
In publication IV the instrumentation consisted of an Agilent Technologies (Waldbronn, Germany) 
1200 Rapid Resolution LC coupled to a Bruker Daltonics HCT Ultra Ion Trap MS with an 
electrospray ion source. The 1200 LC system included a binary pump, vacuum degasser, 
refrigerated model SL autosampler (set at 10 °C) and column oven. The column, a Purospher STAR 
RP-18 endcapped column (55 mm × 4 mm, 3 µm particles; Merck), was kept at 40 °C, the injection 
volume was 5 µL. The ion trap was operated in the standard enhanced scan mode from m/z 300 
to 1200. The ICC target was set to 300000 with a maximum accumulation time of 100 ms. The ion 
source parameters were: dry temperature 365 °C, nebulizer pressure 60 psi and dry gas flow 12 
L/min. The mobile phase consisted of a gradient of 0.1% aqueous formic acid (solvent A) and 
acetonitrile with 0.1% formic acid (solvent B) with the following linear gradient program: 25% B to 
70% B over 5 min, then to 90% B over 2 min, where it was held for 1 min. The injection interval 
was 10 min. Data analysis was performed with the Bruker Compass software version 1.1.  
3.16 Statistics 
Statistical analysis was performed using the Student’s t-test (Microsoft Office Excel). The 
probability level of 5% (P=0.05) was used to indicate the significance. The t-test was used to 
compare the means of the measured variables such as toxin removal percentages. Pearson test 
was used to indicate the correlation between the proteinase activity and the MC-LR removal.  
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4. RESULTS AND DISCUSSION 
The aim of this project was to characterise the potential of probiotic lactic acid bacteria and 
bifidobacteria in removal of cyanobacterial peptide hepatotoxins and the alkaloid cytotoxin 
cylindrospermopsin from aqueous solutions. Different physiological conditions possibly affecting 
the removal efficiency were studied and the mechanism of toxin removal was investigated. 
The results described in the results section highlight the main results presented in detail in 
publications I–IV. 
4.1 Screening of microcystin removal efficiency of probiotic bacterial strains (I) 
Eleven strains of probiotic lactic acid bacteria and bifidobacteria were tested for their MC-LR 
removal capacities. The results showed a reproducible reduction of MC-LR in solution by the 
majority of the tested bacterial strains. Strain differences in the removal of microcystins could be 
noted (Table 4.1). The most efficient removal with lyophilised bacteria was achieved with B. lactis 
Bb12. In addition L. rhamnosus strains GG and LC-705, B. longum 46 and B. lactis 420 showed 
removal percentages of over 20% within 24 h of incubation. The poorest removal was observed 
with L. acidophilus NCFM (3.5%) and L. plantarum Lp-115 (5.7%). 
The removal of MC-LR continued during the entire 24 h incubation, which indicates that the 
removal process is quite slow. Because of the slow removal process, the five strains most efficient 
in microcystin removal in lyophilised form (L. rhamnosus strains GG and LC-705, B. longum 46, B. 
lactis 420 and B. lactis Bb12) were cultured and assayed to compare the removal efficiencies 
between lyophilised and freshly grown bacteria (section 4.2). These five strains were also chosen 
for further studies based on this initial screening experiment. 
4.1.1 Effect of pH 
The effect of pH in the aqueous solution during incubation of bacterial strains with MC-LR was 
studied. pH was found to have an influence on toxin removal, with a higher removal percentage 
observed at neutral pH than at pH 3 (Table 4.1). pH 3 was chosen to examine toxin removal under 
similar conditions as the low pH in the gastrointestinal tract. pH 3 is an intermediate pH value 
occurring between the stomach and the upper intestine. 
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Table 4.1. Percentage of MC-LR removed from solution ± SD at 37 °C by lyophilised 
bacteria
 
  Incubation time 
Strain pH 1h 4h 6h 24h 
B. lactis 420 3 2.3 ± 1.3 8.3 ± 2.0 11.4 ± 2.3 12.1 ± 2.0 
 7 3.4 ± 1.9 9.8 ± 2.6 11.7 ± 2.9 20.7 ± 2.5 
B. lactis Bb12 3 2.0 ± 0.5 9.2 ± 1.4 14.9 ± 2.2 21.0 ± 2.7 
 7 6.8 ± 2.0 17.5 ± 2.6 23.6 ± 3.9 25.7 ± 2.4 
B. lactis HN019 3 1.1 ± 1.3 2.3 ± 1.7 4.9 ± 2.5 12.0 ± 4.4 
 7 0.3 ± 1.5 3.3 ± 0.9 4.3 ± 1.4 14.6 ± 2.4 
B. longum 46 3 1.3 ± 0.4 10.7 ± 2.5 18.1 ± 1.1 21.2 ± 2.0 
 7 1.7 ± 0.8 7.7 ± 0.9 17.4 ± 2.7 23.0 ± 3.3 
L. acidophilus NCFM 3 0.3 ± 0.8 0.9 ± 2.1 1.7 ± 1.3 3.5 ± 1.9 
 7 0.3 ± 0.6 3.4 ± 1.5 4.3 ± 0.9 9.1 ± 2.7 
L. casei Shirota 3 2.9 ± 0.8 9.1 ± 1.6 11.9 ± 1.5 14.8 ± 2.7 
 7 4.6 ± 1.2 9.8 ± 1.4 12.9 ± 0.7 16.2 ± 1.9 
L. fermentum ME3 3 2.3 ± 1.3 8.3 ± 2.0 11.4 ± 2.3 12.1 ± 2.0 
 7 4.6 ± 0.5 10.3 ± 0.7 13.8 ± 1.6 16.3 ± 2.1 
L. plantarum Lp-115 3 2.3 ± 1.3 1.4 ± 2.3 4.2 ± 1.9 5.7 ± 2.6 
 7 0.3 ± 0.9 2.1 ± 2.0 3.3 ± 1.4 6.0 ± 2.9 
L. rhamnosus GG 3 2.1 ± 1.1 11.5 ± 1.2 15.7 ± 1.6 18.2 ± 1.8 
 7 5.5 ± 0.7 8.3 ± 0.9 16.6 ± 1.5 24.3 ± 1.6 
L. rhamnosus LC-705 3 1.9 ± 0.7 10.3 ± 2.0 10.6 ± 0.9 15.0 ± 1.1 
 7 7.0 ± 1.1 13.2 ± 2.7 16.0 ± 3.6 20.6 ± 2.8 
L. salivarius Ls-33 3 0.5 ± 1.5 2.5 ± 2.7 4.4 ± 1.7 11.5 ± 2.5 
 7 0.2 ± 0.4 3.7 ± 2.5 5.3 ± 1.8 19.4 ± 2.3 
Bacterial concentration 8.8 × 109 – 2.7 × 1010 CFU/mL, initial MC-LR concentration 100 µg/L 
 
4.2 Influence of bacterial viability on removal efficiency (I) 
To assess the requirement of viability for removal of MC-LR, the bacteria were inactivated with 
different treatments (ethanol, acid or heat treatment) and the removal capacity of the non-viable 
bacteria was then assessed and compared with that of viable bacteria (Fig. 4.1). For all five strains 
studied (L. rhamnosus strains GG and LC-705, B. longum 46, B. lactis 420 and B. lactis Bb12), viable 
bacteria were shown to be more effective in microcystin removal than non-viable bacteria. The 
removal percentages observed with viable bacteria were 45–65%, while non-viable bacteria 
showed toxin-removal percentages of below 10–20%. Freshly cultured bacteria were shown to be 
more effective in microcystin removal than lyophilised bacteria (Table 4.1). Non-viable bacteria 
could still remove MC-LR to some extent. This could be explained by the fact that the treatments 
can either alter the surface properties of the bacteria, or the microcystins could be bound to 
exposed internal surfaces more suitable for toxin removal, as the bacterial cells probably do not 
stay intact and cell lysis is possible due to the treatment procedures.  
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Lactic acid bacteria have previously been reported to bind various contaminants and toxins, such 
as heavy metals and aflatoxins. It appears that AFB1 is bound to the surface components of lactic 
acid bacteria (Haskard et al., 2001). Heat- and acid-treated bacteria have also been shown to be 
effective in AFB1-removal. The effectiveness of non-viable bacteria suggests that AFB1 is not 
removed by bacterial metabolism, but rather is physically bound probably to the bacterial cell wall 
or cell wall components (El-Nezami et al., 1998b; Haskard et al., 2000; Lee et al., 2003). The 
mechanism of removal of heavy metals has also been shown to be physical adsorption to the cell 
surface (Halttunen et al., 2007a). Therefore it can be concluded that the cyanotoxin-removal 
process by probiotic bacteria differs from the previously reported removal processes of heavy 
metals and aflatoxin. 
 
Figure 4.1. Influence of viability on removal of MC-LR from solution. Non-viable bacteria were 
prepared by ethanol (95%, 30 min), acid (1 M HCl, 30 min) or heat (90 °C, 30 min) treatment. 
Initial MC-LR concentration 100 µg/L, bacterial concentration before treatment 10
10
 CFU/mL, 
incubation time 24 h, temperature 37 °C, pH 7, average ± SD, n = 3. 
 
4.3 Effect of incubation temperature on removal efficiency (I) 
The removal of MC-LR at different temperatures was also assessed. As can be seen in Table 4.2, 
the removal of MC-LR was shown to be temperature dependent, with the highest removal 
observed at 37 °C for all studied strains. This was significantly different (P < 0.05) from the 
removal percentages obtained at 22 °C and 4 °C. Optimal removal was achieved at 37 °C with all 
five strains. At 4 °C, practically no removal of MC-LR could be observed. The removal percentages 
increased with increasing temperature. This can be explained by the fact that at 4 °C, the bacterial 
cells are metabolically inactive, but at 22 and 37 °C, the mesophilic bacteria become metabolically 
active, which is required for enzymatic activity and metabolism. 
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Table 4.2. Percentage of MC-LR removed from solution ± SD at 4 °C, 22 °C and  
37 °C by five strains of probiotic bacteria
 
 Incubation temperature 
Strain 4 °C 22 °C 37 °C 
L. rhamnosus GG 2.6 ± 5.6 17.7 ± 4.5 49.3 ± 2.6 
L. rhamnosus LC-705 2.0 ± 3.0 16.2 ± 3.3 50.3 ± 5.1 
B. longum 46 2.9 ± 4.4 18.1 ± 2.9 47.0 ± 3.2 
B. lactis 420 5.5 ± 2.9 17.3 ± 2.6 47.7 ± 2.0 
B. lactis Bb12 4.1 ± 4.2 22.9 ± 2.2 58.1 ± 4.3 
Bacterial concentration 1010 CFU/mL, initial MC-LR concentration 100 µg/L, 24 h incubation, pH 7 
 
4.4 Removal of different microcystins and cylindrospermopsin (II) 
The results of this study show that specific strains of probiotic bacteria were effective in the 
elimination of several different microcystins and cylindrospermopsin from solution. Table 4.3 
shows the removal of MC-LR, -RR and -LF (one microcystin variant per experiment) by the 
probiotic bacterial strains L. rhamnosus GG and LC-705, B. lactis 420 and Bb12 and B. longum 46 
after 24 h of incubation at 37 °C. All strains showed removal percentages above 45% for all three 
microcystins after 24 h when incubated with one microcystin variant per experiment. The removal 
of cylindrospermopsin was shown to be somewhat less efficient, around 20–30% for all tested 
strains (Table 4.4).  
Simultaneous removal of several toxins present in cyanobacterial extracts was also investigated. 
The time course for the removal of microcystins present in the cyanobacterial extracts Microcystis 
NIES-107 and Microcystis PCC 7820 by the probiotic strain L. rhamnosus GG is shown in Fig. 4.2a 
and b, respectively. The removal of all microcystins increased over time. The rate of removal was 
shown to be at highest during the initial hours of incubation and then gradually decreased. The 
removal of the microcystins present in Microcystis NIES-107 after 24 h of incubation was around 
45–60% of total microcystin and for microcystins present in Microcystis PCC 7820 around 50–75%. 
The toxin-removal was thus shown to be efficient also when several different microcystins were 
present in the solution. This indicates that there is no competition taking place among the toxins 
during incubation with probiotic bacteria.  
The most efficient removal of the cyanotoxins studied was observed for MC-LW and MC-LF (more 
than 70% within 24 h). These microcystins have a more hydrophobic structure compared to MC-
RR or MC-LR. MC-LF and MC-LW are both analogues of MC-LR with phenylalanine and tryptophan 
in place of arginine, and they have been suggested to be more cell-permeable than the more 
hydrophilic microcystins (Kuiper-Goodman et al., 1999). MC-LF and MC-LW have also been shown 
to have higher surface activities in lipid model membrane monolayers as compared to that of the 
more hydrophilic MC-LR (Vesterkvist and Meriluoto, 2003) and thus they might more easily 
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penetrate the membrane. These microcystins could, therefore, be more easily available for 
removal by the bacteria.  
The probiotic bacteria were shown to be relatively effective in cylindrospermopsin removal, but 
the removal efficacy was lower than that observed for microcystins. The structure of the 
cylindrospermopsin molecule, a tricyclic guanidine moiety attached to a hydroxymethyluracil, 
could affect the possible uptake and degradation of the toxin. Microcystins consist of a peptide 
ring, which differs from the cylindrospermopsin structure.  
 
Table 4.3. Percentage of MC-LR, MC-RR or MC-LF separately removed from 
solution ± SD at 37 °C after 24 h incubation  
 Microcystin 
Strain MC-LR MC-RR MC-LF 
L. rhamnosus GG 60.3 ± 3.5 56.0 ± 4.1 72.6 ± 7.1 
L. rhamnosus LC-705 50.3 ± 2.4 62.8 ± 5.4 77.4 ± 1.6 
B. longum 46 47.0 ± 4.2 45.8 ± 5.9 56.0 ± 4.8 
B. lactis 420 49.7 ± 3.7 59.7 ± 3.4 47.8 ± 2.1 
B. lactis Bb12 51.3 ± 3.2 51.4 ± 4.6 51.8 ± 5.4 
Bacterial concentration 1010 CFU/mL, microcystin concentration 100 µg/L 
 
Table 4.4. Percentage of CYN removed from solution ± SD at 37 °C  
 Incubation time 
Strain 5 min 12 h 18 h 24 h 
L. rhamnosus GG 1.3 ± 2.0 20.3 ± 5.2 25.6 ± 3.5 30.6 ± 4.1 
L. rhamnosus LC-705 1.9 ± 1.2 15.1 ± 2.8 19.0 ± 4.6 25.4 ± 2.8 
B. longum 46 0.7 ± 1.4 20.4 ± 3.6 27.7 ± 2.9 31.6 ± 2.9 
B. lactis 420 0.5 ± 0.6 16.1 ± 4.0 20.1 ± 4.4 23.0 ± 3.1 
B. lactis Bb12 0.5 ± 0.9 15.6 ± 3.8 16.2 ± 3.5 22.6 ± 3.4 
Bacterial concentration 1010 CFU/mL, CYN concentration 100 µg/L 
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Figure 4.2. Time course for removal of microcystins in (a) Microcystis NIES-107 and (b) Microcystis 
PCC 7820 by L. rhamnosus GG. Initial concentration of microcystins in Microcystis NIES-107: 13 
µg/L dm-MC-RR, 128 µg/L MC-RR, 24 µg/L MC-YR, and 65 µg/L MC-LR, and in Microcystis PCC 
7820: 108 µg/L MC-LR, 9.4 µg/L MC-LY, 31.4 µg/L MC-LW, and 20.3 µg/L MC-LF, bacterial 
concentration 10
10
 CFU/mL, temperature 37 °C, average ± SD, n = 3. 
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4.5 Comparison of microcystin removal by probiotic strains separately and in combination (II) 
Fig. 4.3 shows the comparison of microcystin removal of three probiotic strains separately and in 
combination. The question of this study was whether a combination of several probiotic strains 
could enhance their microcystin-removal efficiency. The probiotic strains L. rhamnosus GG, L. 
rhamnosus LC-705 and B. longum 46 were incubated with the cyanobacterial extracts Microcystis 
NIES-107 and PCC 7820 at a bacterial concentration of 10
10
 CFU/mL separately or in combination, 
where the total bacterial cell density was 10
10
 CFU/mL (labelled mix in Fig. 4.3). The removal 
percentages of the individual strains after 24 h of incubation were calculated and compared to the 
mixture of the three strains. With the probiotic mixture, microcystin-removal percentages of up to 
80% could be observed. The results show that the removal efficiency was improved with a 
mixture of the strains and the removal percentages observed for the microcystins were 
significantly higher as compared to the individual strains (P <0.05). 
As a result of variations in toxin-removal efficiency of different probiotic strains, combinations of 
bacteria may be beneficial for efficient removal of microcystins from solution. The functionality of 
a multistrain probiotic could be more effective and more consistent than that of a single strain 
(Timmerman et al., 2004). A mixture of several strains could therefore enhance their efficiency 
and improve their toxin removal abilities.  
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Figure 4.3. Removal of MC-LR by individual probiotic strains and a mixture of three strains. (a) 
Removal of microcystins in Microcystis NIES-107 by L. rhamnosus GG, L. rhamnosus LC-705, B. 
longum 46 and mix, (b) removal of microcystins in Microcystis PCC 7820 by L. rhamnosus GG, L. 
rhamnosus LC-705, B. longum 46 and mix. Toxin concentrations same as in Fig. 4.2, bacterial 
concentration 10
10
 CFU/mL, 24 h incubation, temperature 37 °C, average ± SD, n = 3. 
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4.6 Effect of bacterial cell density on toxin-removal efficiency (I) 
To investigate the role of the probiotic bacterial cell density, a range of bacterial cell densities 
were screened (approximately 5 × 10
7
–5 × 10
10
 CFU/mL) and tested for their microcystin-removal 
efficiencies. The removal of MC-LR was shown to be dependent on the bacterial cell density, with 
a minimum of 3 × 10
9
 CFU/mL of strain L. rhamnosus GG required for significant MC-LR removal (P 
< 0.05) (Fig. 4.4; results shown for two probiotic strains; L. rhamnosus GG and B. lactis Bb12). The 
removal of MC-LR was enhanced with increasing bacterial cell density. 
 
Figure 4.4. Effect of bacterial concentration on removal of MC-LR. Initial MC-LR concentration 100 
µg/L, incubation time 24 h, temperature 37°C, pH 7,  average ± SD, n = 3. 
 
4.7 Effect of glucose on microcystin removal (III) 
The aim of this study was to investigate the main factors influencing the metabolic activity and 
enhancing the viability of probiotic strains in removal of MC-LR. In this study, in addition to the 
five commercial probiotic strains used in previous experiments, also the L. plantarum strain Lp-
115 as well as two strains isolated from a traditional Indonesian fermented milk product dadih (L. 
plantarum IS-10506 and IS-20506) were investigated. Dadih, a yogurt-like product, is an 
Indonesian traditional fermented product from West Sumatra, which is spontaneously fermented 
from fresh raw buffalo milk in bamboo tubes and capped with banana leaves (Akuzawa and 
Surono, 2002). Different bacteria, mainly lactobacilli (L. plantarum, L. casei, and others), 
enterococci (E. faecium), and some pediococci can be found in the fermented dadih product 
(Surono and Hosono, 1996; Surono, 2003).  
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 The specific aim of this study was to assess the role of glucose in activating the metabolism of the 
probiotic bacteria. Fig. 4.5 shows the removal percentages of MC-LR for all tested strains at 4 °C 
and 37 °C when suspended in PBS alone, which cannot provide any nutrients to the bacteria, and 
in PBS complemented with 1–3% glucose. The temperatures were chosen to test the influence of 
bacterial metabolic activity on the removal efficiency. A temperature of 4 °C was chosen as the 
temperature at which the probiotic bacteria are metabolically inactive. A temperature of 37 °C is 
the optimal growth temperature for the commercial probiotic bacteria, while the optimal growth 
temperature for the L. plantarum strains is 30 °C (De Angelis et al., 2004). In addition, the 
metabolic activity of the bacteria was influenced by the glucose addition. 
Practically no removal of MC-LR could be observed at 4 °C, whereas at 37 °C all bacterial strains 
tested were able to remove MC-LR (Fig. 4.5) although the removal efficiency was dependent on 
the strain and on glucose addition. The results suggest that bacterial metabolic activity plays an 
important role in toxin removal because at 37 °C, where the bacteria are able to stay 
metabolically active, the removal percentages were highest (P < 0.05) for all tested strains. The 
highest MC-LR removal percentages were obtained at 37 °C using the L. plantarum strains isolated 
from dadih fermented milk. Furthermore, the glucose addition improved the removal efficiencies 
of all tested strains at 37 °C by enhancing both the removal rate and the amount of MC-LR 
removed after 48 h of incubation. In general, glucose had a positive effect on the removal 
abilities, with higher removal percentages observed with the addition of 1% glucose. The addition 
of 2 or 3% glucose did not improve or affect the removal further. At 4 °C, glucose did not have any 
effect on the removal efficiency. 
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Figure 4.5. Percentage of MC-LR removed by freshly cultured bacteria incubated in PBS or PBS 
containing glucose. Initial MC-LR concentration, 100 μg/L; incubation times, 0, 18, 24, and 48 h; 
temperatures 4 °C and 37 °C; 0–3% glucose; average ± SD, n = 3.  
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4.8 Time course for MC-LR removal (I) 
The time course for MC-LR removal (Fig. 4.6) by viable and non-viable bacteria (L. rhamnosus GG 
and B. longum 46) at 22 and 37 °C showed that the removal was the highest during the initial 4 h 
and then decreased gradually. Viable bacteria were efficient in MC-LR removal, while the removal 
percentages for heat-treated bacteria remained below 20% for both tested strains. With higher 
bacterial concentrations, higher removal percentages were observed. The removal percentages 
obtained with non-viable bacteria were low even after an incubation of 24 h. 
The rate of microcystin removal from solution was slow compared with that of the previously 
reported aflatoxin or heavy metal removal, which suggests that the removal mechanisms are not 
the same. Heavy metals are removed within minutes of incubation (Halttunen et al., 2007a) and 
the AFB1-removal has also been reported to be a rapid process (El-Nezami et al., 1998a; Peltonen 
et al., 2001). The rapid removal process as well as the efficiency of non-viable bacteria suggested 
that the removal mechanism of heavy metals and AFB1 is physical binding of the contaminants to 
the probiotic bacterial cells. The exact mechanism of cyanotoxin removal after this study could 
not be reported, but the inefficiency of inactivated bacteria as well as the significance of optimal 
incubation temperature suggested a metabolical activity, such as toxin degradation by the 
bacteria. 
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Figure 4.6. Time course for removal of MC-LR by viable and non-viable bacteria. Non-viable 
bacteria were prepared by heat treatment (90 °C, 30 min). Initial MC-LR concentration 100 µg/L, 
temperatures 22 and 37 °C, pH 7, average ± SD, n = 3. Bacterial concentrations 5 × 10
9
 CFU/mL 
(low) and 5 × 10
10
 CFU/mL (high). 
 
4.9 Flow cytometric analysis of bacterial cell viability (III) 
One specific aim was to assess the importance of cell viability in MC-LR removal. The viability of all 
bacterial strains tested was analysed by both plate counting and the LIVE/DEAD staining kit using 
flow cytometry. Ideally, live bacteria with intact plasma membranes fluoresce green and the dead 
or injured cells with compromised membranes fluoresce red. In accordance with the 
manufacturer’s instructions, all green cells (SYTO9) were considered viable, and red cells (PI) were 
considered dead. The total bacterial population was enumerated by counting green (SYTO9) and 
red microorganisms (PI) using flow cytometry and the results were confirmed by an 
epifluorescence microscope (Fig. 4.7; results shown only for L. rhamnosus GG). The microscopic 
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images showed that in the absence of glucose most of the cells stayed viable until 24 h of 
incubation, while the presence of glucose reduced cell viability markedly already after 24 h of 
incubation. The images also support the conclusion that the bacteria become stressed as a result 
of higher metabolic activity when glucose is added. During incubation, the bacterial strains 
consume glucose and as a consequence produce lactic acid, which in turn causes cell stress as a 
result of the decrease in pH. Consequently, the cells die faster in the presence of glucose. At 37 
°C, the metabolic activity rate is higher in the presence of glucose and the viable cells may 
experience stress as shown by the decrease of viability.  
 
Figure 4.7. Viability of bacteria (L. rhamnosus GG) after 0, 24, and 48 h of incubation at 37 °C in 
the absence or presence of 1% glucose determined by microscopy. Green bacteria: viable; red 
bacteria: non-viable. (a) 0% glucose and (b) 1% glucose. 
 
4.10 Removal of MC-LR by whole cells versus cell extracts (IV) 
The aim of this experiment was to study whether microcystins can be removed by extracts of the 
probiotic bacteria or if viable intact bacteria are needed. The cell extracts were prepared by 
culturing the bacteria, disrupting the cell structure by ultrasonication (checked by microscopy) 
followed by centrifugation (12000 × g, 10 min) and use of supernatant for incubation with MC-LR. 
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Fig. 4.8 shows the comparison of MC-LR removal by cell solutions of L. rhamnosus GG, L. 
rhamnosus LC-705 and B. longum 46 and the cytosolic cell extracts of the same strains. Incubation 
with bacterial cell solutions (10
10
 CFU/mL) showed a 55–70% reduction of MC-LR within 24 h at 37 
°C, which was in accordance with the previous studies. In the presence of bacterial cell extracts 
MC-LR was not removed from solution by any of the three studied probiotic strains (less than 5% 
removal). These findings indicate that activity related to the bacterial cells is needed for efficient 
microcystin removal. 
 
Figure 4.8. Removal of MC-LR by probiotic bacterial cells versus cytosolic cell extracts (L. 
rhamnosus GG, L. rhamnosus LC-705 and B. longum 46). Initial MC-LR concentration 100 μg/L, 
bacterial concentration 10
10
 CFU/mL, temperature 37 °C; average ± SD, n = 3. 
 
4.11 Activity of cell-envelope proteinases and MC-LR removal (IV) 
The participation of cell-envelope proteinases in microcystin removal was investigated. Following 
standard peptidase assay no proteolytic activity against Suc–Ala–Ala–Phe–AMC was found in the 
supernatant obtained by centrifugation of the bacterial cell cultures of the investigated strains L. 
rhamnosus GG, L. rhamnosus LC-705 and B. longum 46. Enzymatic activity was found only in the 
cell suspensions. Enzymatic activity was much higher when measured in cell suspensions 
incubated with glucose than after incubation with PBS (Fig. 4.9) and the activity decreased during 
incubation. After 24 h the activity had disappeared almost completely (not shown).  
Simultaneous analysis of the enzymatic activity and the rate of MC-LR removal indicated that 
these parameters are closely related and both decreased with time (Fig. 4.10; results shown for L. 
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rhamnosus GG; analogous results for L. rhamnosus LC-705 and B. longum 46 in publication IV). 
The enzymatic activity and the concentration of MC-LR were lowered within the first six hours of 
incubation. After 6 h of incubation both the rate of toxin removal and the rate of substrate 
hydrolysis were slowed down. Significant correlation between enzymatic activity and the removal 
of MC-LR was found for three investigated strains (r = 0.88, F = 27.18, P < 0.01 for L. rhamnosus 
GG; r = 0.97, F = 126.5, P < 0.01 for L. rhamnosus LC-705; and r = 0.95, F = 29.5, P < 0.01 for B. 
longum 46). 
 
Figure 4.9. Proteolytic activity of cell suspensions of L. rhamnosus GG measured at 0 h and after 3, 
6 and 9 h of incubation with PBS, 1% glucose and 3% glucose. Cell suspension used in enzyme 
assays was 10
10
 CFU/mL; average ± SD, n = 3. 
 
 
Figure 4.10. The correlation of changes in MC-LR removal and proteinase activity measured within 
24 h of incubation for L. rhamnosus GG. Initial MC-LR concentration 100 μg/L, bacterial 
concentration 10
10
 CFU/mL, temperature 37 °C, average ± SD, n = 3. 
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4.12 Studies with protease inhibitors (IV) 
The activity of cell-associated proteinases of L. rhamnosus GG was measured after incubation with 
different concentrations of protease inhibitors. For EDTA the concentration of inhibitor that 
caused considerable reduction of measured activity was 10 mmol/L (48% of activity in comparison 
with control). Furthermore, proteinases were inhibited at a similar level (60% of activity in 
comparison with control) in the presence of a protease inhibitor cocktail with 10 mmol/L 
concentration of EDTA (Table 4.5 and Fig. 4.11a). It suggested that the main proteolytic activity 
observed for this strain was due to metallo-enzymes. PMSF did not change the activity of cell-
envelope proteinases even at a high concentration (50 mmol/L), whereas almost complete 
abolition of proteolytic activity was observed after incubation with iodoacetic acid (Table 4.5).  
Because EDTA was chosen as a potent proteinase inhibitor, a detailed analysis of its impact on the 
proteolytic activity and removal ability was performed. It was found that the rate of MC-LR 
removal was significantly slower and after 6 h of incubation with bacterial cells only 19% and 10% 
of MC-LR had been removed in the presence of EDTA and protease inhibitor cocktail, respectively 
(Fig. 4.11b). A correlation between proteinase activity and MC-LR removal was also found when 
these parameters were measured simultaneously (Fig. 4.12).  
Experiments with different proteinase inhibitors allowed concluding that metallo-peptidases are 
the main enzymes anchored to the cell wall. This finding is in agreement with other studies, 
because extracellular proteinases identified in lactic acid bacteria are generally metalloenzymes or 
serine proteases (Stefanitsi et al., 1995; Guo et al., 2009). EDTA was shown to inhibit MC-LR 
removal. All these results are in agreement with previous findings that EDTA affects the 
proteinase activity of probiotic bacteria and that this activity is strongly correlated with the 
process of MC-LR removal. 
 
Table 4.5. Proteolytic activity of cell-wall associated proteinases and the viability of L. 
rhamnosus GG cells after 6 h of incubation at 37 °C with EDTA, PMSF, iodoacetic acid or 
protease inhibitor cocktail 
Type of inhibitor                              
Control (PBS + 1% glucose) Cells incubated with inhibitor 
proteolytic activity (µmol/L 
of hydrolyzed substrate/h) 
cell counts 
(CFU/mL) 
proteolytic activity (µmol/L  
of hydrolyzed substrate/h) 
cell counts 
(CFU/mL) 
EDTA (10 mmol/ L) 7.57 ± 0.88 3.0 × 1010 3.66 ± 0.78 2.1 × 1010 
PMSF (50 mmol/L) 7.57 ± 0.88 2.2 × 1010 7.24 ± 1.22 - 
iodoacetic acid (0.1 mmol/L) 7.57 ± 0.88 2.8 × 1010 1.14 ± 0.43 below 105 
protease inhibitor cocktaila 6.87 ± 0.39 3.2 × 1010 4.09 ± 0.14 2.0 × 1010 
Only the values for concentrations causing significant reduction of proteolytic activity are shown; for PMSF the value for 
highest concentration used is presented. 
a final concentrations of inhibitors were 2.32 mmol/L AEBSF, 0.03 mmol/L pepstatin A, 0.2 mmol/L E-64, 0.033 mmol/L 
bestatin and 10 mmol/L sodium EDTA 
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Figure 4.11. The proteolytic activity of cell wall-associated proteinases of L. rhamnosus GG after 
(a) 0.5 h of incubation with different doses of EDTA and (b) the percentage of removed MC-LR 
after 6 h incubation with 10 mmol/L EDTA; average ± SD, n = 3. *values of measured parameters 
in the presence of a protease inhibitor cocktail containing 10 mmol/L of EDTA.  
 
Figure 4.12. MC-LR level and proteinase activity of L. rhamnosus GG incubated in (a) standard 
condition and (b) with 10 mmol/L EDTA; average ± SD, n = 3. 
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4.13 Comparison of MC-LR degradation products for Sphingomonas strains and probiotic 
bacteria (IV) 
Different bacterial strains, other than lactobacilli or bifidobacteria, have previously been shown to 
be able to degrade microcystins enzymatically. Bacterial degradation of microcystins has been 
reported for strains of Sphingomonas (Bourne et al., 1996 and 2001; Harada et al., 2004; Ishii et 
al., 2004). In this study, the removal process of MC-LR by the probiotic strain L. rhamnosus GG 
was compared with two Sphingomonas strains, ACM-3962 and B9, and the degradation products 
were identified. Figure 4.13 shows the HPLC chromatograms for the strains. A reduction of MC-LR 
by the probiotic strain and the two Sphingomonas strains was shown. A maximum removal of 
around 70–80% of MC-LR was observed by L. rhamnosus GG after 24 h of incubation, and the 
removal efficiency of the Sphingomonas strains was similar to that of the probiotic bacteria. In 
addition to reduction of the MC-LR peak, additional peaks were observed for ACM-3962 and B9 
after incubation, whereas with the probiotic strain no new peaks were observed. MC-LR eluted at 
18.1 min, linear MC-LR at 11.5 min and the tetrapeptide degradation product at 13.9 min (Fig. 
4.13). 
The degradation products of MC-LR produced by the Sphingomonas strains were confirmed to be 
the same as previously reported; linearized MC-LR (Adda-Glu-Mdha-Ala-Leu-Masp-Arg-OH) and 
the tetrapeptide (Adda-Glu-Mdha-Ala-OH). The linear MC-LR and the tetrapeptide were seen in 
the HPLC chromatogram of the ACM-3962 strain, but for B9 the linearized MC-LR had already 
been further degraded and only the tetrapeptide was seen (Fig. 4.13). The products and 
degradation patterns (not shown) were identified by HCT Ultra Ion Trap LC-MS (Fig. 4.14 and 
Table 4.6). Linearized MC-LR (major peak m/z 862) and the tetrapeptide (m/z 615) were observed 
for the two Sphingomonas strains. These degradation products were not obtained using the 
probiotic strains, which suggests that the removal mechanisms are not the same. Furthermore, no 
additional degradation products could be identified from samples incubated with the probiotic 
strain.  
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Figure 4.13. Comparison of MC-LR removal by L. rhamnosus GG, Sphingomonas ACM-3962 and 
B9. HPLC chromatograms of bacteria incubated with MC-LR for 24 h at 28 °C (Sphingomonas ACM-
3962 and B9) or 37 °C (L. rhamnosus GG).  
 
 Table 4.6. Degradation products found for Sphingomonas strains 
Toxin or degradation product and fragment ion m/z 
MC-LR [M+H]+ 995.5 
Adda-Glu-Mdha-Ala-Leu-Masp-Arg-OH [M+H]+ 1013.5 
Adda-Glu-Mdha-Ala-Leu-Masp-Arg-OH – NH2 – PhCH2CHOMe  862 
Adda-Glu-Mdha-Ala-OH [M+H]+ 615 
Adda-Glu-Mdha-Ala-Leu-Masp-Arg-OH [M+2H]2+ 507 
HCT Ultra Ion Trap LC-MS analysis  
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Figure 4.14. Comparison of MC-LR removal by L. rhamnosus GG, Sphingomonas ACM-3962 and 
B9. LC-MS chromatograms of bacteria incubated with MC-LR for 24 h at 28 °C (Sphingomonas 
ACM-3962 and B9) or 37 °C (L. rhamnosus GG), showing degradation products (listed in Table 4.6). 
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5. GENERAL DISCUSSION 
The removal of cyanobacterial toxins by probiotic bacteria, both commercial strains of lactic acid 
bacteria and bifidobacteria, and natural strains isolated from the Indonesian dadih fermented 
milk, was investigated in this thesis. The main points of investigation were different factors 
influencing the toxin-removal capacities of the probiotic bacteria and identification of the 
mechanism of toxin-removal.  
Five strains of commercial probiotic bacteria (L. rhamnosus strains GG and LC-705, B. longum 46, 
and B. lactis strains 420 and Bb12) were shown to be the most efficient in microcystin-removal in 
the initial screening study (I) and were chosen for further experiments (II-IV). Different 
physiological conditions potentially affecting the removal efficiency were investigated. These 
included the effect of pH, temperature, toxin concentration, bacterial cell density and cell viability 
(I and II). The cell viability and the impact of glucose a source of energy was then studied more in 
detail (III). Furthermore, the location and mechanism of microcystin removal was investigated by 
studying a possible extracellular enzymatic degradation of microcystins and the degradation 
pathway was compared to other microcystin-degrading bacteria (IV).  
The facts that supported a mechanism involving active toxin elimination instead of physical 
binding in studies I and II were the slow removal process, the enhanced removal percentage at 
optimal growth temperature, the requirement of probiotic bacterial viability and the low recovery 
of eliminated microcystin from bacterial cells. As non-viable bacteria did not have the same ability 
to remove microcystins as viable bacteria, metabolic activity or elimination was suggested as a 
plausible mechanism for microcystin removal. A comparison with the previously reported 
aflatoxin and heavy metal removal suggested that the removal mechanism of cyanotoxins differs 
from the other contaminants. Heavy metals have been shown to be removed within minutes of 
incubation (Halttunen et al., 2007a) and the AFB1-removal has also been reported to be rapid (El-
Nezami et al., 1998a; Peltonen et al., 2001). The rapid removal process as well as the efficacy of 
non-viable bacteria suggested that the removal mechanism of heavy metals and AFB1 is physical 
binding of the contaminants to the probiotic bacterial cells.  
The removal of one microcystin variant, MC-LR, by different probiotic strains, both commercial 
strains and natural strains isolated from the fermented milk product dadih, was investigated 
under different conditions, with different temperatures and bacterial cell densities in the absence 
or presence of glucose, to find the optimal conditions for toxin removal (III). Bacterial viability was 
assessed by traditional plate counting as well as flow cytometry and microscopy. The results of 
this study showed that natural isolated strains from dadih, an Indonesian traditional fermented 
product, were able to remove toxins efficiently up to 48 h, while the removal efficiencies of the 
commercial probiotic strains started to decrease after 24 h of incubation. This could be explained 
by the different viability properties of the bacterial strains observed during incubation, which 
could affect their removal capacities. For the dadih strains, a clear improvement in the removal 
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ability was observed by the addition of glucose as a nutrient source to the solution, but the 
increase was not so marked for the other strains.  
The results further demonstrate that both viability and metabolic activity play important roles in 
the removal of microcystins. Supplementation of glucose provides energy to the bacteria, and 
thereby, the microcystin-removal efficiencies also increase (III). During incubation, the bacterial 
strains consume glucose and as a consequence produce lactic acid, which in turn causes cell stress 
as a result of the decrease in pH. In the studies reported in this thesis, the bacterial cells removed 
MC-LR from solution faster in the presence of glucose but cell death also occurred earlier. 
Differences between the bacterial strains could be observed both in their microcystin-removal 
properties and in the viability of the bacteria during incubation.  
The results reveal that cell viability, bacterial cell density, cell culturability, and metabolic activity 
play important roles in the removal of MC-LR (III). As a consequence of active metabolism, the 
viable cells become exhausted and stressed. Consequently, besides resulting in high removal 
ability, supplementation of glucose also resulted in decreased viability. In response to lack of 
energy or stress conditions, many bacteria are able convert into a viable but non-culturable 
condition (VBNC). Bacteria that have reached the VBNC state are unable to grow in conventional 
media but still maintain their membrane integrity and indicators of metabolic activity (Rollins and 
Colwell, 1986; Colwell, 2000; Lowder et al., 2000; Pruzzo et al., 2002). In other words, they enter 
an active but non-culturable state. This may be potentially reversed by provision of nutritionally 
rich culture media and optimal growth conditions (Yamamoto, 2000; Oliver, 2005). The results of 
this study suggest that the metabolic activity of the bacteria is maintained functional in the cells, 
which can be detected by the enhanced removal of MC-LR at 37 °C in the presence of glucose. 
Furthermore, the microscopic images support the fact that glucose enhances the metabolic 
activity of the cells, and thereby, the cells become stressed and cell death occurs earlier. 
Different bacterial strains, other than lactobacilli or bifidobacteria, have been shown to be able to 
degrade microcystins enzymatically. Bacterial degradation of microcystins has previously been 
reported for naturally occurring bacterial strains (Cousins et al., 1996; Park et al., 2001; Harada et 
al., 2004; Kato et al., 2007). Bourne et al. (1996) described an enzymatic pathway for the bacterial 
degradation of toxic cyclic peptides mediated by hydrolytic enzymes of Sphingomonas species. 
The degradation products were identified as linearized MC-LR and further degradation to a 
tetrapeptide. The probiotic strains studied in this research work could possibly utilise a similar 
kind of mechanism for MC-LR removal, which was investigated in study IV. The GRAS status of 
probiotic lactic acid bacteria would give them an advantage for usage in microcystin-removal.  
Previous studies with Sphingomonas strains (Bourne et al., 2001; Ishii et al., 2004) have indicated 
that the key enzyme involved in microcystin degradation is present in the periplasmic space. The 
findings of this thesis indicate that the process of microcystin-removal in the presence of probiotic 
bacteria differs from the known mechanism of biodegradation that occurs in the cells of 
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Sphingomonas. The key enzyme involved in microcystin-degradation in Sphingomonas strains, 
MlrA, is present in the periplasmic space and digested peptides are transported into the cell by 
specific transporters (Bourne et al., 2001; Ishii et al., 2004).  
Based on the results of study IV it can be concluded that no activity against MC-LR is present in 
the cytosolic fraction of the investigated probiotic strains, which excludes the involvement of 
intracellular proteases in the process of MC-LR removal. Additionally, the studies with 
14
C-
radiolabelled microcystins showed that MC-LR is not transported into the cells of probiotic 
bacteria during the incubation with bacterial cells but stayed in the supernatant during the whole 
incubation. Furthermore, cytosolic bacterial cell extracts were not able to remove MC-LR. It was 
concluded that the peptide transport system is not involved in the process of microcystin-removal 
and degradation inside the cell by cytosolic proteases is not present in the probiotic bacteria. 
Consequently, the participation of cell-envelope proteinases in microcystin removal was 
investigated. A large increase of enzymatic activity was observed after addition of glucose to the 
solution during incubation. These findings suggest that an energy source is required to maintain 
high proteolytic activity and, in addition, glucose consumption may be responsible for the 
decrease of this activity. The proteolytic system present in all species of lactic acid bacteria was 
therefore the natural candidate for research regarding enzymatic removal of toxins by the 
probiotic bacteria (IV). It is composed of extracellularly located proteinases involved in the initial 
cleavage of casein to peptides, peptidases that hydrolyze the large peptides thus formed into 
smaller peptides, and amino-acids and peptide transport systems involved in the cellular uptake 
of the hydrolytic products (Law and Haandrikman, 1997). Simultaneous analysis of the enzymatic 
activity and the rate of MC-LR removal indicated that these parameters are closely related and 
both decreased with time.  
In summary, the results presented in this thesis have for the first time provided evidence that 
probiotic bacteria may efficiently remove cyanobacterial toxins from aqueous solutions. The 
correlation between the activity of cell-envelope proteinases and the decrease of MC-LR 
concentration suggests that enzymes are involved in microcystin removal. The findings strongly 
support the theory that enzymatic degradation of microcystin occurs when the toxin is incubated 
with cell suspensions of probiotic bacteria.  
Lactic acid bacteria and bifidobacteria interact with toxin producing microbes and some toxins as 
well as viruses and pathogens present in food and water. The main future objective would 
therefore be to understand probiotic health effects and to relate the mechanisms and actions to 
future potential of specific probiotic bacteria in decontamination of foods and water. The complex 
interaction of microbes with other members of the gut microbiota and the host also forms the 
basis for assessing interactions between the probiotic bacteria and toxins, as well as other 
contaminants. The studies of this thesis have focused on the removal of cyanobacterial toxins, but 
to assess the usefulness of probiotics as biological decontaminants, also interactions with 
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potentially pathogenic bacteria, fungal toxins and viruses should be taken into account to be able 
to define future applications in human health promotion. The use of probiotics as a personal 
defence mechanism against cyanotoxins could be a potential area of use. Probiotic dietary 
supplements could possibly be used as a personal defence against cyanotoxins in the 
gastrointestinal tract and to reduce the health risks caused by microcystins in drinking water.  
Previous reports have showed that biological degradation of cyanotoxins may be a feasible 
method of water treatment. By the results obtained in this thesis, probiotic bacteria show 
potential in biological decontamination of cyanotoxin-containing water. Biological 
decontamination of drinking water by probiotic bacteria could therefore be another potential 
target of use. The probiotic bacterial strains or possible enzymes identified in the removal process 
could be used in a bioremediation process to remove toxins from drinking water. Bacteria 
immobilised on a filter might be a useful approach for the removal of contaminants such as heavy 
metals and mycotoxins, for which non-viable bacteria have been shown to be efficient removers. 
On the other hand, for efficient removal of cyanotoxins, metabolically active viable bacteria are 
needed, which could be a challenge for the potential filter-approach. In addition, the optimal 
removal temperature of 37 °C, the high cell density needed, the relatively long treatment time as 
well as the requirement of a bacterial nutrient source could be a challenge for an efficient water 
treatment process. The re-use of bacterial cells in the treatment process should further be 
assessed. The acids secreted in the fermentative metabolism of carbohydrates by probiotics 
should also been taken into account, as acidification of water could be a possible outcome. 
Instead, other technologies of biological decontamination could be considered. Recombinant 
technologies using potential purified enzymes identified in the removal process of probiotic 
bacteria could be a future approach for efficient cyanotoxin removal. 
In conclusion, the development of new treatment technologies by low-cost probiotic bacteria and 
specific probiotic combinations that would be able to remove or inactivate both mycotoxins, 
cyanotoxins, heavy metals, viruses and pathogenic bacteria is an important aspect to consider in 
the future. These kinds of probiotic combinations could be used for decontamination of both 
water and food and could provide new options for the removal of the contaminants mentioned. 
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6. CONCLUSIONS 
Toxic cyanobacteria have been reported in lakes and reservoirs around the world. The presence of 
toxins in drinking water creates a potential risk of toxin transference for water consumers. 
Besides chemical and physical methods of cyanotoxin removal from water, biodegradation 
methods would be useful. The majority of cyanotoxin biodegradation studies have focused on 
bacteria isolated from water sources exposed to microcystin-containing blooms. The results of 
this thesis present a new type of bacteria, specific probiotic bacterial strains, to be efficient in 
cyanotoxin removal. Probiotic bacteria have several advantages in comparison with the previously 
reported microcystin-degrading bacteria, as they have been classified as food grade, safe bacteria 
by EFSA (2010). Therefore probiotic bacteria can safely be included in both food and water, and 
can also safely be used in food technology. Furthermore, the beneficial health effects of probiotic 
bacteria give them an advantage for the use in different applications.  
The first aim of this study was to screen a number of specific strains of probiotic lactobacilli and 
bifidobacteria for their capacity to remove microcystins from water solutions and to evaluate 
their potential for water decontamination (I). Several strains were shown to be efficient in toxin 
removal and different physiological conditions, including the effect of pH, temperature, toxin 
concentration, bacterial cell density and cell viability, optimal for removal were investigated (II). 
The removal of several different cyanotoxins was also studied (II). The third specific aim was to 
further investigate the role of bacterial viability and how it could be affected by different factors 
to achieve optimal toxin removal (III). The fourth aim of the study was to identify bacterial 
removal mechanisms of one of the cyanotoxins studied, the hepatotoxin MC-LR (IV). This was 
studied by comparison of the degradation pathway of previously identified microcystin-degrading 
bacteria with the probiotic strain, and by investigating the possible location for toxin degradation. 
An extracellular enzymatic degradation of microcystins by probiotic bacteria was tested and it was 
suggested that extracellularly located cell-envelope proteinases appear to be involved in the 
decomposition of MC-LR. In particular, a correlation between proteolytic activity and MC-LR 
removal was found. 
The main human exposure route of microcystins is considered to be the oral route. Eighty percent 
of microcystin exposure has been estimated to occur through drinking water (Kuiper-Goodman et 
al., 1999). The removal of microcystins in drinking water is, therefore, of great importance and 
probiotic bacteria show promising results in this respect. They could consequently have 
applications both in biological decontamination of microcystin-containing water and as a personal 
defence against microcystins in the gastrointestinal tract. There is a high demand for effective and 
low-cost approaches for removing cyanotoxins from potable water due to the significant health 
risk and inadequate access to safe drinking water. Bacterial bioremediation is a promising and 
potentially effective means for removal of cyanotoxins (Bourne et al., 1996; Ho et al., 2007) and 
probiotic bacterial strains may contribute to treatment strategies. 
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